DLQI – Published Articles

1994

– Finlay AY, Khan GK.  Dermatology Life Quality Index (DLQI): A simple practical measure for routine clinical use.Clinical and Experimental Dermatology 1994; 19: 210-216.

1995

– Kurwa H, Finlay AY.  Dermatology inpatient management greatly improves life quality. British Journal of Dermatology 1995; 133: 575-578.

1996

– Blackford S, Roberts DL, Salek MS, Finlay AY.  Basal cell carcinomas cause little handicap.Quality of Life Research 1996; 5: 191-194.

– Finlay AY.  Measures of the effect of severe atopic eczema on quality of life.Journal of the European Academy of Dermatology and Venereology, 1996; 7: 149-154.

– Harris A, Burge SM, Dykes PJ, Finlay AY.  Handicap in Darier’s disease and Hailey-Hailey disease.  British Journal of Dermatology 1996; 135: 959-963.

– Jemec GB, Wulf HC.  Patient-physician consensus on quality of life in dermatology.  Clinical and Experimental Dermatology 1996; 21: 177-179.

– Kent G,  Al-Abadie M.  Factors affecting responses on Dermatology Life Quality Index items among vitiligo sufferers.Clinical and Experimental Dermatology 1996; 21: 330-333.

– Nichol MB, Margoilies JE, Lippa E, Rowe M, Quell J.  The application of multiple quality of life instruments in individuals with mild-to-moderate psoriasis.   Pharmacoeconomics 1996; 10: 644-653.

– Piletta P A, Wirth S et al.  Circulating skin-homing T cells in atopic dermatitis.  Arch Dermatol 1996; 132: 1171-1176.

1997

– Blackford S, Finlay AY, Roberts DL.  Quality of life in Behcets’ syndrome: 335 patients surveyed.British Journal of Dermatology 1997; 136: 293.

– Finlay AY.  Quality of life measurement in dermatology: a practical guide.  British Journal of Dermatology 1997; 136: 305-314.

– Herd RM, Tidman MJ, Ruta DA, Hunter JAA.  Measurement of quality of life in atopicdermatitis: correlation and validation of two different methods.  British Journal of  Dermatology 1997; 136: 502-507.

– Newton JN, Mallon E, Klassen A, Ryan TJ, Finlay A.  The effectiveness of acne treatment: an assessment by patients of the outcome of therapy.  British Journal of Dermatology 1997; 137: 563-567.

1998

– Bagel J, Garland W T, Breneman D et al.  Administration of DAB 389 IL-2 to patients with recalcitrant psoriasis:  A double-blind, phase II multicentre trial. J Am Acad of Dermatol 1998; 38: 938-944.

– de Tiedra AG, Mercadal J, Badia X, Mascaró JM, Herdmann M, Lozano R.  Adaptación transcultural al Español del cuestionario Dermatology Life Quality Index (DLQI): el Índice de Calidad de Vida en Dermatologia.Actas Dermo-Sifiliograficas 1998; 89: 692-700.

– de Tiedra AG, Mercadal J, Badia X, Mascaró JM, Lozano R.  A method to select an instrument for measurement of HR-QOL for cross-cultural adaptation applied to dermatology.  Pharmacoeconomics 1998; 14: 405-422.

– Finlay AY.  Dermatology Life Quality Index: initial experience of a simple practical measure.    Chapter in: Care management of skin disease: Life quality and economic impact.  Editors: R Rajagopalan, E.F. Sherertz, R.T. Anderson.  Marcel Dekker, New York 1998 p85-94.

– Finlay AY.  Quality of life assessments in dermatology.  Seminars in Cutaneous Medicine and Surgery 1998; 17: 291-296.

– Grosshans E et al.  Evaluation of clinical efficacy and safety of adapelene 0.1% gel versus tretinoin 0.025% gel in the treatment of acne vulgaris, with particular reference to the onset of action and impact on quality of life.  British Journal of Dermatology 1998; 139 (Suppl 52): 26-33.

– Iliev D, Furrer L, Elsner P.  Estimating the quality of life of dermatologic patients.  Hautarzt 1998; 49: 453-456.

1999

– Augustin M, Zschocke I, Lange S, Seidenglanz K, Amon U.  Quality of life in skin diseases:  methodological and practical comparison of different quality of life questionnaires in psoriasis and atopic dermatitis.  Hautarzt 1999; 50: 715-22.

– Badia X, Mascaro JM, Lozano R.  Measuring health-related quality of life in patients with mild to moderate eczema and psoriasis: clinical validity, reliability and sensibility to change of the DLQI.  British Journal of Dermatology 1999; 141: 698-702.

– Linnet J, Jemec GBE.  An assessment of anxiety and dermatology life quality in patients with atopic dermatitis.  British Journal of Dermatology 1999; 140: 268-272.

– Lundberg L, Johannesson M, Silverdahl M, Hermansson C, Lindberg M.  Quality of life, health-state utilities and willingness to pay in patients with psoriasis and atopic eczema.  British Journal of Dermatology 1999; 141: 1067-1075.

– Mallon E, Newton JN, Klassen A, Stewart-Brown SL, Ryan TJ, Finlay AY. The quality of life in acne: a comparison with general medical conditions using generic questionnaires.  British Journal of Dermatology 1999; 140: 672-676.

– Papadopoulos L et al.  Coping with the disfiguring effects of vitiligo. British Journal of Medical Psycholog 1999; 72: 385-396.

– Poon E, Seed PT, Greaves MW, Kobza-Black A.  The extent and nature of disability in different urticarial conditions.  British Journal of Dermatology 1999; 140: 667-671.

2000

– Ayyalaraju R S, Finlay A Y.  Inpatient Dermatology:  United Kingdom and United States similarities.  Chapter in Dermatologic Clinics:  Inpatient Dermatology.  Eds F A Kerdel, R S  Kisner. W B Saunders Co, Philadelphia Dermatologic Clinics 2000; 18(3): 397-404

– Czech W, Brautigam M, Weidinger G, Schopt F.  A body-weight-independent dosing regimen of cyclosporine microemulsion is effective in severe atopic dermatitis and improves the quality of life.  J Am Acad Dermatol 2000; 42: 653-659.

– Finlay A Y  Dermatology patients:  what do they really need?  Clin Exp Dermatol 2000; 25: 444-450

– Giess R, Naumann M, Werne E, Riemann R, Beck M, Puls I, Reiners C, Toyka K V.  Injections of botulinum toxin A into the salivary glands improve sialorrhoea in amyotrophic lateral sclerosis.  J Neurol Neurosurg Psychiatry 2000; 69: 121-123.

– Halioua B, Beumont M G.  Quality of life in dermatology.  International Journal of Dermatology 2000; 39: 801-806

– Harlow D, Poyner T, Finlay A Y, Dykes P J.  Impaired quality of life in adults with skin disease in primary care.  British Journal of Dermatology 2000; 143: 979-982.

– Haynes M.  Examining day-case and in-patient psoriasis care. Professional Nurse 2000; 16: 893-896.

– Hutchings CV, Shum KW, Gawkrodger DJG.  Occupational contact dermatitis has an appreciable impact on quality of life.  British Journal of Dermatology 2000; 143 (Suppl 57): 27.

– Jobanputra R, Bachmann M.  The effect of skin diseases on quality of life in patients from different social and ethnic groups in Cape Town, South Africa.  International Journal of Dermatology 2000; 39: 826-831.

– Kernick D, Cox A, Powell R, Reinhold D, Sawkins J, Warin A.  A cost consequence study of the impact of a dermatology-trained practice nurse on the quality of life of primary care patients with eczema and psoriasis.  British Journal of General Practice 2000; 50: 555-558.

– Klassen A F, Newton J N, Mallon E.  Measuring quality of life in people referred for specialist care of acne:  comparing generic and disease-specific measures.  Journal of the American Academy of Dermatology2000; 43: 229-233.

– Lundberg L, Johannesson M, Silverdahl M et al.  Health-related quality of life in patients with psoriasis and atopic dermatitis measured with SF-36, DLQI and a subjective measure of disease activity.  Acta Derm Venereol 2000; 80: 430-434.

– Marks R, Plunkett A, Merlin K, Jenner N.  Atlas of Common Skin Diseases in Australia.  University of Melbourne, Melbourne 2000 p9, 15, 19.

– Shum RW, Lawton S, Williams HC, Docherty G, Jones J.  The British Association of Dermatologists audit of atopic eczema management in secondary care.  Phase 3:  audit of service outcome.BritishJournal of Dermatology 2000; 142: 721-727.

– Thompson A K, Finn A F, Schoenwetter W F.  Effect of 60 mg twice-daily Fexofenadine HCI on quality of life, work and classroom productivity, and regular activity in patients with chronic idiopathic urticaria.Journal of the American Academy of Dermatology 2000; 43: 24-30

– Vensel E, Hilley T, Trent J, et al.  Sustained improvement of the quality of life of patients with psoriasis after hospitalisation.  J Am Acad Dermatol 2000; 43: 858-860.

– Zachariae R, Zachariae C. Ibsen H, Mortensen J T, Wulf H C. Dermatology life quality index:  data from Danish inpatients and outpatients.  Acta Derm Venereol 2000; 80: 272-276.

2001

– Drake L, Prendergast M, Maher R et al.  The impact of tacrolimus ointment on health-related quality of life of adult and pediatric patients with atopic dermatitis.  J Am Acad Dermatol 2001; 44: S65-S72.

– Finlay A Y.  Psoriasis from the patient’s point of view.  Arch Dermatol2001; 137:  352-353

– Hahn BH, Melfi CA, Chuang T Y et al.  Use of the Dermatology Life Quality Index (DLQI) in a Midwestern US Urban Clinic.  J Am Acad Dermatol 2001; 45: 44-48.

– Hiltscher D, Boslet W T, Fuchslocher M et al.  Quality of life in patients with rosacea and rhinophyma.  Akt Dermatol 2001; 27:  391-394

– Ho V C Y, Griffiths C E M, Berth-Jones J et al.  Intermittent short courses of cyclosporin microemulsion for the long-term management of psoriasis:  a 2 year cohort study.  J Am Acad Dermatol 2001; 44: 643-651.

– Hutchings C V, Shum K W, Gawkrodger D J.  Occupational contact dermatitis has an appreciable impact on quality of life.  Contact Dermatitis 2001; 45(1): 17-20.

– Jemec BG B E, Kynemund L.  Time spent on treatment in dermatology – how much time do outpatients use and is it a measure of morbidity? Acta Dermatoven APA 2001; 10:17-19

– Poli F, Dreno B, Vershoores M.  An epidemiological study of acne in female adults:  results of a survey conducted in France.  JEADV 2001; 15: 541-545

– Schafer T, Staudt A, Ring J.  German instrument for the assessment of quality of life in skin diseases (DIELH).  Internal consistency, reliability, convergent and discriminant validity and responsiveness.  Hautarzt2001; 52(7): 624-628.

– Swan M C, Paes T.  Quality of life evaluation following endoscopic transthoracic sympathectomy for upper limb and facial hyperhydrosis.  Ann Chir Gynaecol 2001; 90(3): 157-159.

– Swartling C, Naver H, Lindberg M.  Botulinum A toxin improves life quality in severe primary focal hyperhidrosis.  Eur J Neurol 2001; 8: 247-52

– Touw C R, Hakkaart-Van Roijen L, Verboom P, Paul C, Rutten F F H, Finlay A Y.  Quality of life and clinical outcome in psoriasis patients using intermittent cyclosporin.  Br J Dermatol 2001; 144: 967-972

– Von Der Werth J  M, Jemee G B E.  Morbidity in patients with hidradenitis urativa.
Br J Dermatol 2001; 144: 809-813.

– Williams T L, May C R, Esmail A, et al.  Patient satisfaction with teledermatology is related to perceived quality of life.  Br J Dermatol2001; 145: 911-917.

– Williamson D, Gonzalez M, Finlay A Y.  The effect of hair loss on quality of life.
J Eur Acad of Dermatol & Venereol 2001; 15: 137-139.

2002

– Boehncke W H, Ochsendorf F, Paeslack I, Kaufmann R, Zollner T M. Decorative cosmetics improve the quality of life in patients with disfiguring skin diseases.  Eur J Dermatol 2002; 12(6): 577-580.

– Fivenson D, Arnold R J G, Kaniecki D J, Cohen J L, Frech F, Finlay A Y.  The effect of atopic dermatitis on total burden of illness and quality of life on adults and children in a large managed care organisation. J Managed Care Pharmacy 2002; 8(5): 333-342

– Gradwell C, Thomas K S, English J S, Williams H C. A randomised controlled trial of nurse follow-up clinics: do they help patients and free up consultants’ time?  Br J Dermatol 2002; 147: 513-517.

– Hachem J P, DePaepe K, Sterckx G, Kaufman L, Rogiers V, Roseeuw D.  Evaluation of key biographical and clinical parameters of skin barrier function among hospital workers.  Contact Dermatitis 2002; 46: 220-223.

– Helbling I, Ferguson J E, McKenna M, Muston H L.  Audit of admissions to dermatology beds in Greater Manchester.  Clin & Exp Dermatol 2002; 27: 519-522

– Hermansen S E, Helland C A, Finlay A Y.  Patients’ and doctors’ assessment of skin disease handicap.  Clin & Exp Dermatol 2002; 27: 249-250.

– Holme S A, Beattie P E, Fleming C J. Cosmetic camouflage advice improve quality of life.  Br J Dermatol 2002; 147: 946-949.

– Horn H M, Tidman M J.  Quality of life in epidermolysis bullosa.  Clin Exp Dermatol 2002; 27(8):  707-710.

– Jayaprakasam A, Darvey A, Osborne G, McGibbon D.  Comparisons of assessment of severity and quality of life in cutaneous disease.  Clin Exp Dermatol 2002; 27: 306-8.

– Kiebert G, Sorensen S V, Revicki D, Fagan, S C, Doyle J J, Cohen J, Fivenson D.  Atopic dermatitis is associated with a decrement in health-related quality of life.  Int J Dermatol 2002; 41: 151-8.

– Loo W-J, Lanigan S W.  Laser treatment improves quality of life of hirsute females.  Clin & Exp Dermatol 2002; 27(6): 439-441.

– Meurer M, Folster-Holst R, Wozel G, Weindinger G, Junger M, Brautigam M.  Primecrolimus cream in the long-term management of atopic dermatitis in adults:  A six-month study.Dermatology 2002; 205(3): 271-277.

– Mork C & Wahl A, Polit R N.  Improved quality of life among patients with psoriasis after supervised climate therapy at the Canary Islands. J Am Acad Dermatol 2002; 47: 314-36.

– Mork C, Wahl A, Moum T.  The Norwegian version of the Dermatology Life Quality Index:  a study of validity and reliability in psoriatics.  Acta Derm Venereol 2002; 82: 347-351.

– Thomson K F, Wilkinson S M, Sommer S, Pollock B.  Eczema: quality of life by body site and the effect of patch testing.   Br J Dermatol 2002; 146: 627-630.

2003

– Ayyalaraju R S, Finlay A Y, Dykes P J, Trent J T, Kirsner R S, Kerdel F A.  Hospitalization for severe skin disease improves quality of life in the United Kingdom and the United States:  A comparative study.  JAAD2003; 49: 249-254.

– Balkrishnan R, McMichael A J, Camacho F T, Saltzberg F, Housman Grummer S, Feldman S R, Chren M M.  Development and validation of a health-related quality of life instrument for women with melasma.  Br J Dermatol 2003; 149(3): 572-577.

– Bergstrom K G, Arambula K, Kimball A B.  Medication formulation affects quality of life: randomized single-blind study clobetasol propionate foam 0.05% compared with a combined program of clobetasol cream 0.05% and solution 0.0.5% for the treatment of psoriasis.  Cutis 2003; 72(5): 407-411.

– Campanati A, Penna L, Guzzo T, Menotta L, Silvestri B, Lagalla G, Gesuita R, Offidani.  Quality of life assessment in patients with hyperhidrosis before and after treatment with botulinum toxin:  results of an open-label study.  Clin Ther 2003; 25: 298-308.

– Carlin C S, Feldman S R, Krueger J G, Menter A Krueger C G.  A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint.  J Invest Dermatol 2003; 121(1): 0393.andJAAD 2004; 50(6): 859-866.

– Chan J J, Gebeuer K.  Treatment of severe recalcitrant plaque psoriasis with single-dose intravenous tumour necrosis factor-alpha antibody (infliximab).  Australas J Dermatol 2003; 44(2): 116-20.

– Charman C. Chambers C, Williams H.  Measuring atopic dermatitis severity in randomized controlled clinical trails:  What exactly are we measuring?  J Invest Dermatol 2003; 120 (6): 932-941.

– Ellis C N, Mordin M M Adler E Y.  Effects of Alefacept on health-related quality of life in patients with psoriasis:  Results from a randomised, placebo controlled phase II trial.  Am J Clin Dermatol 2003; 4(2):  131-139.

– Finlay A Y, Salek M S, Haney J.  Intramuscular alefacept improves health-related quality of life in patients with chronic plaque psoriasis. Dermatology 2003; 206(4): 307-315.

– Finlay A Y.  The impact of acne on quality of life.  J Am Acad Dermatol2003; 49: 133-135.

– Goffe B, Cather J C.  Etanercept:  An overview.   Am Acad Dermatol2003; 49 (2): S105-S111.

– Gordon K B, Papp K A, Hamilton T K, Walicke P A, Dummer W, Li N, Bresnanhan B W, Menter A.  Efalizumab for patients with moderate to severe plaque psoriasis: a random controlled trial.  JAMA 2003; 290(23): 3073-3080.

– Gottlieb A B, Matheson R T, Low N, Krueger G G, Kang S, Goffe B S, Gaspari A A, Ling M, Weinstein G D, Nayak A, Gordon K B, Zitnik R.  A randomized trial of etanercept as monotherapy for psoriasis.  Arch Dermatol 2003; 139: 1627-1632.

– Krueger G G, Callis K P.  Development and use of alefacept to treat psoriasis.   Am Acad Dermatol 2003; 49 (2): S87-S97.

– Leonardi C L, Powers J L, Matheson R T, Goffe B S, Zitnik R, Wang A, Gottlieb A B, for the Etanercept Psoriasis Study Group.  Etanercept as monotherapy in patients with psoriasis.  New England J of Med2003; 349 21: 2014-2022.

– Leonardi C L.  Efalizumab:  An overview.  Am Acad Dermatol 2003; 49 (2): S98-S104.

– Littenberg B, Partilo S, Licata A, Kattan M W.  Paper Standard Gamble:  the reliability of a paper questionnaire to assess utility.  Med Decis Making 2003; 23(6): 480-488.

– Loo W-J, Diba V, Chawla M, Finlay A Y.  Dermatology Life Quality Index: influence of an illustrated version. Br J Dermatol 2003; 148:  279-284.

– Mazzotti E, Picardi A, Sampogna F, Sera F, Pasqunini P, Abeni D,.  The Idi multipurpose psoriasis research on vital experiences (improve) study group.  Sensitivity of the Dermatology Life Quality Index to clinical change in patients with psoriasis. Br J Dermatol 2003 149(2): 318-322.

– McKenna S P, Cook S A, Whalley D, Doward L C, Richards H L, Griffiths C E M, Van Assch D.  Development of the PSORIQoL, a psoriasis-specific measure of quality of life designed for use in clinical practice and trials.  Br J Dermatol 2003; 149(2): 323-331.

– McPherson T.  Impact on the quality of life of lymphoedema patients following introduction of a hygiene and skin care regimen in a Guyanese community endemic for lymphatic filariasis: A preliminary clinical intervention study. Filaria Journal 2003; 2: 1

– Parsad D, Pandhi R, Dogra S, Kanwar A J, Kumar B.  Dermatology Life Quality Index score in vitiligo and its impact on the treatment outcome.Br J Dermatol 2003; 148; 2: 373-374.

– Pittler M H, Armstrong N C, Cox A, Collier P M, Hart A & Ernst E. Randomized, double-blind, placebo-controlled trial of autologous blood therapy for atopic dermatitis.  Br J Dermatol 2003; 148(2): 307-313.

– Reilly M C, Lavin P T, Kahler K H, Pariser D M.  Validation of the Dermatology Life Quality Index and the Work Productivity and Activity Impairment – Chronic Hand Dermatitis questionnaire in chronic hand dermatitis.  J Am Acad Dermatol 2003; 48: 128-130.

– Schmid-ott G, Burchard R, Niederauer H H, Lamprecht F,Kunsebeck H W. Stigmatization and quality of life of patients with psoriasis and atopic dermatitis.  Hautarzt 2003; 54(9): 852-857.

– Shikiar R, Bresnahan B W, Stone S P, Thompson C, Koo J, Revicki D A,Validity and reliability of patient reported outcomes used in psoriasis:  results of two randomised clinical trials.  Health Qual Life Outcomes 2003; 1(1): 53.

– Skoet R, Zachariae R, Agner T.  Contact dermatitis and quality of life:  a structured review of the literature.  Br J Dermatol 2003; 149: 452-456.

– Weisman S, Pollack C R, Gottschalk R W.  Psoriasis disease severity measures: comparing efficacy of treatments for severe psoriasis.  J Dermatol Treatment 2003; 14: 158-165.

– Woo P N, Hay I C, Ormerod A D.  An audit of the value of patch testing and its effect on quality of life.  Contact Dermatitis 2003; 48: 244-247.

2004

– Aghaei s, Sodaifi M, Jafari P, Mazharinia N, Finlay A Y.  DLQI scores in vitiligo:  reliability and validity of the Persian version.  BMC Dermatol2004; 4(1): 8.

– Augustin M, Wenninger K, Amon U, Schroth M J, Kuster W. Chren M, Kupfer J, Gieler U.  German adaptation of the Skindex-29 questionnaire on quality of life in dermatology:  Validation and clinical results. Dermatology 2004; 209: 14-20.

– Blanch J, Rousaud A, Martinez E, De Lazzari E, Milinkovic A, Peri J M, Blanco J L, Jaen J, Navarro V, Massana G, Gatell J M.  Factors associated with severe impact of lipodystrophy on the quality of life of paints infected with HIV-1.  Clin Infect Dis 2004; 38(10): 1464-1470.

– Charman C R, Venn A J, Williams H C.  The patient-oriented eczema measure.  Arch Dermatol 2004; 140: 1513-1519.

– de Korte J, Sprangers M A G, Mombers F M C, Bos J D. Quality of life in patients with psoriasis: a systematic literature review.  J Investig Dermatol Symp Proc 2004; 9(2):140-147.

– Feldman S R, Menter A Koo JY.  Improved health-related quality of life following a randomized controlled trial of alefacept treatment in patients with chronic plaque psoriasis.  BJD 2004; 150: 317-326.

– Finlay A Y Quality of Life Indices.  Indian J Dermatol Venereol Leprol2004; 70: 144-149.

– Ganemo A, Sjoden P O, Johansson E, Vahlquist A, Lindbert M.  Health-related quality of life among patients with ichthyosis.  Eur J Dermatol2004; 14(1): 61-66.

– Gottlieb A B, Evans R, Li S, Dooley L T, Guzzo C A, Baker D, Bala M, Marano C W & Menter A.  Infliximab induction therapy for patients with severe plaque-type psoriasis:  A randomized, double-blind, placebo-controlled trial.  .  JAAD 2004; 51(4) 534-542.

– Holm E A, Esmann S, Jemec G B E.  Does visible atopic dermatitis affect quality of life more in women than in men?  Gender Medicine2004; 1(2): 125-130.

– Jenner N, Campbell J, Marks R.  Morbidity and cost of atopic eczema in Australia.  Australas J Dermatol 2004; 45(1): 16-22.

– Kaltwasser J P, Nash P, Gladman D, Rosen C F, Behrens F, Jones P, Wollenhaupt J, Falk F G, Mease P. Efficacy and Safety of Leflunomide in the Treatment of Psoriatic Arthritis and Psoriasis: a multinational, double- blind, randomised, placebo- controlled clinical trial.Arthritis & Rheumatism 2004; 50 (6): 1939 – 1950

– Kulthanan K, Jiamton S, Wanitphakdeedecha R, Chantharujikaphong S.  The validity and reliability of the Dermatology Life Quality Index  (DLQI) in Thais.  Thai J Dermatol 2004; 20(3):  113-123.

– Lennox R D, Leahy M J.  Validation of the Dermatology Life Quality Index as an outcome measure for urticaria-related quality of life.  Ann Allergy Asthma Immunol 2004; 93(2): 142-146.

– Lewis V L, Finlay A Y.  Ten years experience of the Dermatology Life Quality Index (DLQI)J Investig Dermatol Symp Proc 2004; 9(2):169-180.

– Meding B, Wallenhammar L-M, Lindberg M, Nyfjall M.  Health-related quality of life and hand eczema.  Contact Dermatitis 2004; 50(3): 152-153.

– Menter A, Kosinski M, Bresnahan B W, Papp K A, Ware J E Jr.  Impact of efalizumab on psoriasis-specific patient-reported outcomes.  Results from three randomized, placebo-controlled clinical trails of moderate to severe plaque psoriasis.  J Drugs Dermatol 2004; 3(1): 27-38.

– Meurer M, Fartasch M, Albrecht G, Vogt T, Worm M, Ruzicka T, Altmeyer P J, Schneider D, Weidinger G, Braeutigam M.  Long-term efficacy and safety of pimcrolimus cream 1% in adults with moderate atopic dermatitis.  Dermatology 2004; 208: 365-372.

– Mork C, Ozek M, Wahl A K.  Treatment or leisure?  Climate therapy of patients with psoriasis and psoriatic arthritis.  Tidsskr NorLaegeforen2004; 124(1): 60-62.

– Nettis E, Colanardi M C, Paradiso M T, Ferrannini A. Desloratadine in combination with montelukast in the treatment of chronic urticaria: a randomized, double – blind, placebo- controlled studyClin Exp Allergy2004: 4: 1401 – 1407.

– Rhee J S, Matthews B A, Neuburg M, Smith T L, Burzynski M, Nattinger A B.  Skin cancer and quality of life:  assessment with the Dermatology Life Quality Index.  Dermatol Surg 2004; 30(4): 525-9.

– Ruzicka T, Larsen F G, Galewicz D, Horvath A, Coenraads P J, Thestrup-Pedersen K, Ortonne J P, Zouboulis C C, Harsch M, Brown T C, Zultak M.  Oral Alitetinoin (9-cis-retinoic acid) Therapy for chronic hand dermatitis in patients refractory to standard therapy.  Arch Dermatol2004; 140: 1453-1459.

– Sampogna F, Sera F, Abeni D; IDI Multipurpose psoriasis research on vital experience (IMPROVE) investigators.  Measure of clinical severity, quality of life, and psychological distress in patients with psoriasis:  a cluster analysis.  J Invest Dermatol 2004; 122 (3): 602-607.

– Szepietowski,J, Salomon J, Finlay A Y, Klepacki A, Chodynicka B, Marionneau N, Taieb C, Myon E.  DLQI:  Polish version.  Dermatlogia Kliniczna 2004; 6(2): 63-70.

– Tan S R, Whitney D T.  Pulsed dye laser treatment of rosacea improves erythema, symptomatology, and quality of life.  JAAD 2004; 51(4) 592-599.

– Uttjek M, Dufaker M, Nygren L, Stenberg B.  Determinants of quality of life in a psoriasis population in northern Sweden.  Acta Derm Venereol2004; 84(1):  37-43.

– Wallenhammar L M, Nyfjall M, Lindberg M, Meding B.  Health-related quality of life and hand eczema – a comparison of two instruments, including factor analysis.  J Invest Dermatol 2004; 122(6): 1381-1389,JID 2004; 122(6): 1381-1387.

– Wang X L, Zhao T E, Zhang X O.  Assessment on the reliability and validity of the Dermatology Life Quality Index in Chinese version.  Zhonghau Liu Xing Bing Xue Za Zhi 2004; 25(9): 791

– Wells M, Macmillan M, Raab, G, Macbride S, Bell N, MacKinnon K, MacDougall H,
Samuel L, Munro A.  Does aqueous or sucralfate cream affect the severity of erythematous radiation skin reaction?  A randomised controlled trial.  Radiother Oncol 2004; 73(2):  153-162.

– Whalley D, McKenna S P, Dewar A L. Erdman R A, Kohlmann T, Niero M, Cook S A, Crickx B, Herdman M J, Frech F, Assche D Van.  A new instrument for assessing quality of life in atopic dermatitis: international development of the Quality of Life Index for Atopic Dermatitis (QoLIAD).  BJD 2004; 150: 274-283.

– Wittkowski A, Richards H L, Griffiths C E, Main C J.  The impact of psychological and clinical factors on quality of individuals with atopic dermatitis.  J Psychosom Res 2004; 57(2):  195-200.

– Won C, Seo P, Park Y, Yang J, Lee K, Sung K, Park C, Kim D, Char Won Y, Kim K.  A Multicentre trial of the efficacy and safety of 0.03% tacrolimus ointment for atopic dermatitis in Korea.  J Dermatolog Treat2004; 15(1): 30-34.

– Yazici K, Baz K, Yazici A, Kokturk A, Tot S, Demirserent D, Butural  Disease-specific quality of life is associated with anxiety and depression in patients with acne.  J Eur Acad Dermatol Venereol 2004; 18(4): 435-439.

– Zachariae R, Zachariae C, Ibsen H H, Mortensen J T, Wulf H C. Psychological symptoms and quality of life of dermatology outpatients and hospitalized dermatology patients.  Acta Derm Venereol 2004; 84: 205-212.

– Zaghloul S S, Goodfield M J D.  Objective assessment of compliance with psoriasis treatment.  Arch Dermatol 2004; 140: 408-414.

2005

– Al-Buainian H, Gamal H, Cruz D, Alhayki N, Ongenae K, Naeyaert J N, allam M I.  The impact of vitiligo on quality of life in patients from Jeddah, Saudi Arabia. 

– Agarwal S, Ramam M, Sharma V K, Khandpur S, Pal H, Pandey R M. A randomized placebo- controlled double- blind study of levamisole in the treatment of limited and slowly spreading vitiligo.BJD 2005; 153: 163 – 166.

– Babu B V, Nayak A N, Rth K, Kerketta A S.  Use of the Dermatology Life Quality Index in filarial Lymphoedema patients.  Trans of the R Soc Trop Med & Hyg 2005; 11:

– Charman C R, Venn A J, Williams H, Bigby M.  Measuring atopic eczema severity visually.  Arch Dermatol:  2005; 141:  1146-1151.

– Chuh A A, Chan H H.  Effect on quality of life in patients with pityriasis rosea:  Is it associated with rash severity?  Int J Dermatol 2005; 44(5): 372-377.

– Coast J, Noble S, Nobel A, Horrocks S, Asim O, Peters T J, Salisbury C. Economic evaluation of a general practitioner with special interest led dermatology service in primary care.  BJM 2005 331: 1444-1448.

– David S E, Ahmed Z, Salek M S, Finlay A Y.  Does enough quality of life-related discussion occur during dermatology outpatient consultations? BJD 2005; 153: 997-1000.

– Feldman S R, Gordon K B, Bala M, Evans R, Dooley L T, Guuzzo C, Patel K, Menter A, Gottlieb A B.  Infliximab treatment results in significant improvement in the quality of life of patients with sever psoriasis:  a double-blind placebo-controlled trial.  BJD 2005; 152:  954-960.

– Feldman S R, Kimball A B, Krueger G G, Woolley J M, Llalla D, Jahreis A.  Etanercept improves the helath-related quality of life of patients with psoris:  Resutls of a phse III randomized clinical trial.  J Am Acad Dermatol 2005; 53:887-889.

– Finlay A Y.  Current severe psoriasis and the Rule of Tens.  BJD 2005; 152: 861-867.

– Hartmann A, Lurz C, Hamm H, Brocker E B, Hofmann U B.  Narrow-band UVB vs broad-band UVB therapy in combination with topical calcipotriol vs. placebo in vitiligo.  Int J Dermatol 2005; 44(9): 736-742.

– Holm E A, Esmann S, Jemec.  Patient Education and morbidity in atopic eczema.  Dermatol Nursing 2005; 17(1): 35-45.

– Hongbo Y, Thomas C L,. Harrison M A. Salek M S, Finlay A Y. Translating the science of quality of life into practice:  what do Dermatology Life Quality Index scores mean?  JID 2005; 125 (4): 659-664.

– Ilgen E, Derya A.  There is no correlation between acne severity and AQOLS/DLQI scores.   Journal of Dermatology 2005; 32(9): 705-710.

– Innocenzi D, Lupi F, Bruni F, Frasca M, Panetta C, Milani M.  Efficacy of a new aluminium salt thermophobic foam in the treatment of axillary and palmar primary hyperhidrosis:  a pilot exploratory trial.  Curr Med Res Opin 2005; 21(12): 1949-1953.

– Jacobi A, Antoni C, Manger B, Schuler G, Hertl M.  Infliximab in the treatment of moderate to severe atopic dermatitis.  J Am Acad Dermatol 2005; 52(3): 522-526.

– Katugampola R P, Hongbo Y, Finlay A Y.  Clinical management decisions are related to the impact of psoriasis on patient-rated quality of life.  BJD 2005; 152: 1256-1262.

– Kondoh A, Ohta Y, Yamamoto K, Iwashita K, Umezawa Y, Matsuyama T, Ozawa A, Shinohara Y.  Feasibility of modified DLQI-based questionnaire for evaluation of clinical efficacy of herbal medicine in chronic skin diseases.  Tokai J Exp Clin Med 2005; 30(2):  97-102.

– Krueger G G, Langley R G, Finlay  A Y, Griffiths C E M, Woolley J M, Lalla D, Jahreis A.  Patient-reported outcomes of psoriasis improvement with etanercept therapy:  results of a randomized phase III trial.  BJD2005; 153: 1192-1199.

– Mayrshofer F, Hertl M, Sinkgraven R, Sticherling M, Pfeiffer C, Zillikens D, Messer G, Rzany Fur Die Deutschebsd-Studiengrouppe B. Significant decrease in quality of life in patients with pemphigus vulgaris.  Results from the German Bullous Skin Disease (BDS) Study Group.  J Dtsch Dermatol Ges. 2005; 3(6): 431-435.

– Mazzotti E, Barbaranelli C, Picardi A, Abeni D, Pasquini P. Psychometric properties of the Dermatology Life Quality Index  (DLQI) in 900 Italian patients with psoriasis.  Acta Derm Venereol 2005; 85: 409-413.

– McKenna S P, Lebwhol M, Kahler K N.  Development of the US PSORIQoL:  A psoriasis-specific measure of quality of life.  Intern J of Dermatol 2005; 44: 462-469.

– Menter A, Gordon K, Carey W, Hamliton T, Glazer S, Caro I, Li N, Gulliver W.  Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis.  Arch Dermatol 2005; 141(1) 31-38.

– Moloney F J, Keane S, O’Kelly P, Conlon P J, Murphy G M.  The impact of skin disease following renal transplantation on quality of life.  Br J Dermatol 2005; 153 (3):  574-578.

– Ongenae K, Dierckxsen L, Brochez L, van Geel N, Naeyaert J M.  Quality of life and stigmatization profile in a cohort of vitiligo patients an effect of the use of camouflage.  Dermatology 2005; 210: 279-285. 

– Ongenae K, Van Geel N, De Schepper S, Naeyaert J M.  Effect of vitiligo on self-reported health –related quality of life.  BJD 2005; 152: 1165-1172.

– Ortonne J P, Shear N, Shumack S, Henninger E, CLEAR Multinational Study Group.  Impact of efalizumab on patient-reported outcomes in high-need psoriasis patients:  results of the international, randomized, placebo-controlled Phase III Clinical Experience Acquired with Raptiva (CLEAR) trial (NCT 00256139).  BMC Dermatol 2005; 5: 13.

– Öztas P, Calikoglu E, Cetin I.  Psychiatric test in seborrhoeic dermatitis.  Acta Derm Venereol 2005; 85: 68-69.

– Polderman M C, Wintzen M, Cessie S, Pavel S.  UVA-1 cold light therapy in the treatment of atopic dermatitis:  61 patients treated in the Leiden University Medical Center.  Photodermatol Photoimmunol Photomed 2005; 21(2):93-96.

– Rottem M, Elbirt D, Sthoeger Z, Desloratadine Study Group. Desloratadine for chronic idiopathic urticaria.  Harefuah 2005; 144(8): 547-553, 599, 598.

– Salisbury C, Nobel A, Horrocks S, Crosby Z, Harrison V, Coast J, de Berker D, Peters T.  Evaluation of a general practitioner with special interest service for dermatology randomised controlled trial.  BJM2005 331: 1441-1443.

– Schmitt J, Wozel G.  The Psoriasis Area and Severity Index is the adequate criterion to define severity in chronic plaque-type psoriasis. Dermatology 2005; 210: 194-199.

– Shah M, Coates M.  An assessment of the quality of life in odder patients with skin disease.  BJD 2005; 154: 150-153.

– Shikiar R, Harding G, Leahy M, Lennox R D.  Minimal Important Difference (MID) of the Dermatology Life Quality Index  (DLQI):  Results from patients with chronic idiopathic urticaria.  Health Qual Life Outcomes 2005;3: 36.

– Smith C H, Anstey A V, Barker JNWN, Burden A D, Chalmers R J G, Chandle D, Finlay A Y, Griffiths C EM , Jackson S, McHugh N J, McKenna K E, Reynolds N J, Ormerod A D.  British Association of Dermatologist guidelines for use of biological interventions in psoriasis 2005. –  BJD2005; 153: 486-497.

– Tjioe M, Otero M E, van der Kerkhof P C M, Gerritsen M J P.  Quality of life in vitiligo patients after treatment with long-term narrowband ultraviolet B phototherapy.  JEADV 2005; 19: 56-60.

– van de Kerkhof P, Griffiths C E M, Christophers E, Lebwohl M, Krueger G G.  Alefacept in the treatment of psoriasis in patients for whom conventional therapies are inadequate.  Dermatology 2005; 211: 256-263.

– Weiss S C, Nguyen J, Chon S, Kimball A B.  A randomized controlled clinical trial assessing the effect of betamethasone valerate 0.12% foam on the short-terms treatment of stasis dermatitis.  J Drugs Dermatol 2005; 4(3): 339-345.

– Yahathugoda T C, Wickramasinghe D, Weerasooriya M V, Samarawickrema W A.  Lymphoedema and its management in cases of lymphatic filariasis:  the current situation in three suburbs of Matara, Sri Lanka, before the introduction of a morbidity-control programme. Ann Trop Med Parasitol 2005; 99: (5): 501-510.

– Zaghloul S S, Cunliffe W J, Goodfield M J D.  Objective assessment of compliance with treatments in acne.  BJD 2005; 152:  1015-1021.

2006

– Asawanonda P, Nateetongrungsak Y. Methotrexate plus narrowband UVB phototherapy versus narrowband UVB phototherapy alone in the treatment of plaque- type psoriasis: A randomized, placebo – controlled study.J Am Dermatol 2006; 54(6): 1013 – 1018

– Baron S E, Morris P K, Dye L, Fielding D, Goulden V.  The effect of dermatology consultations in secondary care on treatment outcome and quality of life in new adult patients with atopic dermatitis.  BJD2006; 154: 942-949.

– Bickers D R, Lim H W, Margolis D, Weinstock M A, Goodman C, Faulkner E, Gould C, Gemmen E, Dall T.  The burden of skin diseases:  2004.  A joint project of the American Academy of Dermatology Association and the Society for Investigative Dermatology.
J Am Acad Dermatol 2006; 3: 490-500.

– Boehncke W-H, Brasie R A, Barker J, Chinenti S, Dauden E, de Rie M, Dubertret L, Giannetti A, Katsambas A, Kragballe K, Naeyaert J M, Ortonne J-P, Peyri J, Prinz J C, Saurat J-H, Strohal R, van de Kerkhof  P. Recommendations for the use of etanercept in psoriasis:  a European dermatology expert group consensus.  JEADV 2006; 20: 988-998.

– Borimnejad L, Parsa Yekta Z, Nikbakht-Nasrabadi A, Firooz A.  Quality of life with vitiligo:  comparison of male and female Muslim patients in Iran.  Gend Med 2006; 2: 124-130.

– Brooklyn T N, Dunnill M G S, Shetty A, Bowden J J, Williams J D L, Griffiths C E M, Forbes A, Greenwood R, Probert C S. Infliximab for the treatment of pyoderma gangrenosum: a randomized, double blind, placebo controlled trial.Gut 2006; 55: 505- 509

– Cassano N, Loconsole F, Galluccio A, Icracapillo A, Pezza M, Vena G A. Once-weekly administration of high-dosage Etanercept in patients with plaque psoriasis:  results of a pilot experience (power study).  Int J Immunopathol Pharmacol 2006; 19(1): 225-229

– Conroy F J, Venus M, Monk B.  A qualitative study to assess the effectiveness of laser epilation using a quality-of-life scoring system. Clin Exp Dermatol. 2006 31(6): 753-756.

– Cusack C, Buckley C.  Etanercept:  effective in the management of hidradenitis suppurativa.  BJD 2006; 154: 726-729.

– Cvethkovski B S, Zachariae R, Jensen H, Olsen J, Johansen J D, Agner T.  Prognosis of occupational hand eczema.  Arch Dermatol 2006; 142: 305-311.

– Cvetkovski R S, Zachariae R, Jensen H, Olsen J, Johansen J D, Agne T.   Quality of life and depression in a population of occupational hand eczema patients.  Contact Dermatitis 2006; 54: 106-111.

– Dalgard F, Finlay A Y.  Need and Greed in Dermatology:  Disease and outcome measures in dermatological healthcare planning. Dermatology 2006; 213: 279-283.

– de Felice C, Mazzotta A, Esposito M, Bianchi L, Chimenti S.  High-dose initiation of etanercept in psoriatic arthritis and plque psoriasis:  Efficacy, safety and impact on patient’s quality of life.  J Dermatol Treat2006; 17: 355-358.

– Ferraz L B, de Almeida F A, Vasconcellos M R, Faccina A S, Ciconelli R M, Ferraz M B.  the impact of lupus erythematosus cutaneous on the quality of life:  The Brazilian-Portuguese version of DLQI.  Qual Life Res2006; 15(3) 565-570.

– Finlay A Y.  The DLQI:  A patient questionnaire can improve clinical decision-making in treating skin disease.  MIMS Dermatology 2006; 2(2): 12.

– Gladman D D, Mease P J, Cifaldi M A, Perdok R J, Sasso E, Medich J. Adalimumab improves joint – and skin-related functional impairment in patients with psoriatic arthritis:  Patient-reported outcomes of the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT).  Ann Rhuem Dis 2006 Oct (E-Pub ahead of print).

– Godse K V. Quality of life in chronic urticariaIndian J Dermatol 2006; 51: 155 – 157

– Gordon K, Korman N, Frankel E, Want H, Jahreis, Zitnik R, Chang T. Efficacy of etanercept in an integrated multi-study database of patients with psoriasis.  J Am Acad Dermatol2006; 54 (3): A101.

– Gottlieb A B, Mease P J, Jackson M, Eisen D, Xia H A, Asare C, Stevens S R.  Clinical characteristics of psoriatic arthritis and psoriasis in dermatologists’ offices.  J Derm Treat 2006; 17: 279-287.

– Holm E A, Wulf H C, Stegmann H, Jemec G B E.  Life quality assessment among patients with atopic eczema.  BJD 2006; 154: 719-725.

– Holm E, Esmann S, Jemec G.  The handicap caused by atopic dermatitis – sick leave a job voidance.  JEADV 2006; 20(3): 255-259.

– Holme S A, Anstey A V, Finlay A Y, Elder G H, Badminton M N. Erythropoietic protoporphyria in the UK:  clinical features and effect on qualify of life.  BJD 2006; 155: 574-581.

– Hundley J L, Carroll C L, Lang W, Snively B, Yosipovitch G, Feldman S R, Jorizzo J L.  Cutaneous symptoms of dermatomyositis significantly impact patients; quality of life.  J Am Acad Dermatol 2006; 54 (2) 217.

– Kapp A, Pichler W J.  Levocetirizine is an effective treatment in patients suffering from chronic idiopathic urticaria:  a randomized, double-blind, placebo-controlled, parallel, multicentre study.  Int J Dermatol 2006;45: 469-474.

– Lachapelle J, Dexroix J, Henrijean A, Roquet-Gravy P, De Swerdt A, Boonen H, Lecuyer M, Suys E, Speelman G, Vastesaeger N. Desloratadine 5mg once daily improves the quality of life of patients with chronic idiopathic urticaria.   JEADV 2006; 20(3): 288-292.

– Lorette G, Ermosilla V. Clinical efficacy of a new ciclopiroxolamine/zinc pyrithione shampoo in scalp seborrheic dermatitis treatment. Eur J Dermatol. 2006 Sep-Oct; 16(5):558-564.

– Maroti M, Ulff E, Wijma B.  Quality of life before and 6 weeks after treatment in a dermatological outpatient treatment unit.  J Eur Acad Dermatol Venerol 2006; 9: 1081-1085.

– Matsuoka Y, Yoneda K, Sadahira C, Katsuura J, Moriue T, Kubota Y.Effects of skin care and makeup under instructions from dermatologists on the quality of life of female patients with acne vulgaris.J Dermatol. 2006 Nov;33(11):745-52.

– Mechri A, Amri M, Douarika AA, Ali Hichem BH, Zouari B, Zili J.Psychiatric morbidity and quality of life in Vitiligo: a case controlled study. [Article in French].Tunis Med. 2006 Oct; 84(10):632-5.

– Meggitt S J, Gray J C, Reynolds N J.  Azathioprine dosed by thiopurine methyltransferase activity for moderate-to-severe atopic eczema:  a double-blind, randomised controlled trial.  The Lancet 2006; 367: 839-846.

– Nijsten T, Meads D M, McKenna S P.  Dimensionality of the Dermatology Life Quality Index (DLQI):  A Commentary.  Acta Derm Venereol 2006; 86(3): 284-285.

– Öztürkcan S, Ermertcan A.T, Eser E and Şahin M.T. Cross validation of the Turkish version of dermatology life quality index.International Journal of Dermatology 2006, 45, 1300-1307.

– Reich K, Nestle F O, Papp K, Ortonne J-P, Wu Y, Bala M, Evans R, Guzzo C, Li S, Dooley L T, Griffiths C E M.  Improvement in quality of life with infliximab induction and maintenance therapy in patients with moderate-to-severe psoriasis:  a randomized controlled trial.  BJD2006; 154: 1161-1168.

– Ryoji T, Masatoshi I, Hironobu I, Miyako T, Kimiko O, Wakae A, Katsuhiko Y, Katsuki O, Akira I, Yoshinori S. Improvement of QOL of Vitiligo Patients using Make- up Cosmetic to Conceal Hypopigmentation.Skin Research 2006; 5 (1): 72 – 80

– Salim A, Tan E, Ilchyshyn A, Berth-Jones J.  Folic acid supplementation during treatment of psoriasis with methotrexate:  a randomized, double-blind, placebo-controlled trial.   BJD 2006; 154: 1169-1174.

– Sampogna F, Chren M M, Melchi E F, Pasquini P, Taboli S, Abeni D & The Italian Multipurpose Psoriasis research on Vital Experience (Improve)Study Group.  Age, gender, quality life and psychological distress in patients hospitalized with psoriasis.  BJD 2006; 154: 325-331

– Sampogna F, Tabolli S, Söderfeldt B, Axtelius B, Aparo U, Abeni D & IDI Multipurpose Psoriasis Research on Vital Experiences (IMPROVE) investigators.  Measuring quality of life of patients with different clinical types of psoriasis using the SF-36.  BJD 2006; 154: 844-849.

– Schmitt J M, Ford D E.  Work limitations and productivity loss are associated with health-related quality of life but not with clinical severity in patients with psoriasis.  Dermatology 2006; 213: 102-110.

– Shaymaa E M, El Shahat F A, Wafaa E B. Atopic Dermatitis: Relation Between Disease Severity, Anxiety and Quality of Life in Children and Adults.Egyptian Dermatology Online Journal 2006; 2 (1)

– Shikiar R, Willian, M K, Okun M M, Thompson C S, Revicki D A.  The validity and responsiveness of three quality of life measures in the assessment of psoriasis patients:  results of a phase II study.  Health Qual Life Outcomes 2006; 4: 71.

– Smith C H, Jackson K, Bashir S J, Perex A chew A L, Powell A M, Wain M, Barker J N W N.  Infliximab for severe treatment-resistant psoiais:  a prospect, open-label study.  BJD 2006 155: 160-169.

– Staubach P, Onnen K, Vonend A, Metz M, Siebenhaar F, Tschentscher I, Opper B, Magerl M, Ludtke R, Kromminga A, Maurer M. Autologous Whole Blood Injections to Patients with Chronic Urticaria and a Positive Autologous Serum Skin Test: A Placebo- Controlled Trial.Dermatology 2006; 212: 150- 159

– Sunderkotter C, Weiss J M, Betermoller R, Loffler H, Schneider D.  Post-marketing surveillance on treatment of 5,665 patients with atopic dermatitis using the calcineurin inhibitor pimecrolimus:  positive effects on major symptoms of atopic dermatitis and on quality of life. J Dtsch Dermatol Ges 2006; 4(4): 301-306.

– Takahashi N, Suzukamo Y, Nakamura M, Miyachi Y, Green J, Ohya Y, Finlay A Y, Fukuhara S; Acne QoL Questionnaire Development Team. Japanese version of the Dermatology Life Quality Index:  validity and reliability in patients with acne.  Health Qual Life Outcomes 2006; 4: 46.

– Türel Ermertcan A, Temeltaş G, Deveci A, Dinç G, Güler HB, Oztürkcan S. Sexual dysfunction in patients with psoriasisJ Dermatol. 2006 Nov;33(11):772-8.

– Tyring S, Gottlieb A, Papp K, Gordon K, Leonardi C, Wang A, Lalla D, Woolley M, Jahreis A, Zitnik R, Cella D, Krishnan R. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double- blind placebo- controlled randomised phase III trial.Lancet 2006; 367:29 – 35

– van Coevorden A M, van Sonderen E, Bouma J, Coenraads P JJ. Assessment of severity of hand eczema:  discrepancies between patient- and physician-rated scores.  BJD 2006; 155: 1217-1222.

– van Geel N, Ongenae K, Vander Haeghen Y, Vervaet C, Naeyaert J M. Subjective and objective evaluation of non-cultured epidermal cellular grafting for re-pigmenting vitiligo.  Dermatology 2006; 213(1): 23-29.

– Vena G A, Cassano N, Colombo D, Peruzzi E, Pigatto P and the NEO-1-30 Study Group, Bari, Origio & Milan, Italy.  Cyclosporine in chronic idiopathic urticaria:  a double-blind, randomized, placebo-controlled trial.  J Am Acad Dermatol 2006; 55(4): 705-709.

– Wahl A K, Mork C, Hanestad B R, Helland S.  Coping with exacerbation in psoriasis and eczema prior to admission in a dermatological ward. Eur J Dermatol 2006; 16(3): 271-275.

– Wahl A K, Mork C, Mork Lillehol B, Myrdal A M, Helland S, Hanestad B R, Moum T.  Changes in quality of life in persons with eczema and psoriasis after treatment in departments of dermatology.  Acta Derm Venereol 2006;  (86) 3: 198-201.

– Weissenbacher S, Merkl J, Hildebrandt B, Wollenberg A, Breautigam M, Ring J & Hofmann H.  Pimecrolimus cream 1% for papulopustular rosacea:  a randomized vehicle-controlled double-blind trial.  BJD2006; 156: 728-732.

– Woolacott N, Hawkins N, Mason A, Kainth A, Khadjesari Z, Vergel YB, Misso K, Light K, Chalmers R, Sculpher M, Riemsma R. Etanercept and efalizumab for the treatment of psoriasis: a systematic reviewHealth Technol Assess. 2006 Nov; 10(46):1-233, i-iv.

– Yasuo K, Tetsuya M, Junko K, Yoshie M, Kozo N, Ikumi Y, Yasushi M, Kozo Y. Topical sequential therapy using maxacalcitol ointment and corticosteroid in psoriasis vulgaris: with the entry of quality of life.Japanese Journal of Clinical Dermatology 2006; 60 (12); 1178 – 1185

2007

– [No authors listed]. Results of leflunomide treatment of psoriatic arthritis. [Article in Russian]. Ter Arkh. 2007; 79(8): 22-8.

– Al – Ghnaniem R, Short K, Pullen L C, Rennie J A, Leather A J. 1% hydrocortisone ointment is an effective treatment of pruritus ani: a pilot randomised controlled crossover trialInt J Colorectal Dis 2007; May (E-pub).

– Al Robaee A A. Assessment of quality of life in Saudi patients with vitiligo in a medical school in Qassim province, Saudi Arabia.Saudi Med J. 2007 Sep;28(9):1414-1417.

– Antoniou C, Stefanaki I, Stratigos A, Avgerinou G, Stavropoulos P, Potouridou I, Polidorou D, Moustou A E, Kosmadaki M & Katsambas A D. The Greek experience with efalizumab in psoriasis from a university dermatologic hospital.  BJD 2007; 156 (Suppl 2): 12-16.

– Basra M K A, Sue-Ho R, Finlay A Y.  The Family Dermatology life Quality Index:  measuring the secondary impact of skin disease.  BJD 2007; 156: 528-538.

– Bechara F G, Gambichler T, Bader A, Sand M, Altmeyer P, Hoffmann K.Assessment of quality of life in patients with primary axillary hyperhidrosis before and after suction- curettageJ Am Acad Dermatol2007; 56(2): 207 – 212.

– Belhadjali H, Amri M, Meecheri  A, Doarika A, Khorchani H, Youssef M, Gaha, Zili J. Vitiligo and quality of life: a case- control study (Article in French)Ann Dermatol Venereol 2007; 134 (3 Pt 1) 233 – 236.

– Both H, Essink- Bot M E, Busschbach J, Nijsten T. Critical Review of Generic and Dermatology- Specific Health- Related Quality of Life InstrumentsJID 2007; 127: 2726 – 2739

– Campanati A, Bernardini M L, Gesuita R, Offidani A. Plantar focal idiopathic hyperhidrosis and botulinium toxin: a pilot studyEur J Dermatol 2007; 17(1): 52 – 54 (E- pub).

– Chaidemenos GC, Mourellou O, Avgoustinaki N, Papakonstantinou M, Karakatsanis G, Katsambas A. Intermittent vs. continuous 1-year cyclosporin use in chronic plaque psoriasis. J Eur Acad Dermatol Venereol. 2007 Oct;21(9):1203-8.

– Chandrasena TG, Premaratna R, Muthugala MA, Pathmeswaran A, de Silva NR. Modified Dermatology Life Quality Index as a measure of quality of life in patients with filarial lymphoedema.Trans R Soc Trop Med Hyg. 2007 Mar;101(3):245-9.

– Chen S C. Dermatology Quality of Life Instruments: Sorting Out the Quagmire.JID 2007; 127, 2685 – 2696

– Coghi S, Bortoletto M C, Sampaio S A, Andrade Jr HF, Aoki V. Quality of life is severely compromised in adult patients with atopic dermatitis in Brazil, especially due to mental componentsClinics 2007; 63(3): 235 – 242.

– Eghlileb A M, Davies E E G, Finlay A Y.  Psoriasis has a major secondary impact on the lives of family members and partners.  Br J Dermatol 2007; 156: 1245-1250.

– Elewski B, Leonardi C, Gottlieb A B, Strober B E, Simiens M A, Dunns M, Jahareis A.  Comparison of clinical and pharmacokinetic profiles of etanercept 25mg twice weekly and 50mg one weekly in patient with psoriasis.  BJD 2007; 156: 138-142.

– Garduno J, Bhosle M J, Balkrishnan R, Feldman S R. Measures used in specifying psoriasis lesion(s), global disease and quality of life: A systematic reviewJ Dermatolog Treat 2007; 18(4): 223 – 242.

– Grob JJ. Why are quality of life instruments not recognized as reference measures in therapeutic trials of chronic skin disorders? J Invest Dermatol. 2007 Oct;127(10):2299-301.

– Heinen-Kammerer T, Daniel D, Stratmann L, Rychlik R, Boehncke WH.Cost-effectiveness of psoriasis therapy with etanercept in Germany. [Article in English, German]J Dtsch Dermatol Ges. 2007 Sep;5(9):762-8

– Katugampola R P, Lewis VJ, Finlay A Y.  The Dermatology Life Quality Index:  assessing the efficacy of biological therapies for psoriasis.  Br J Dermatol 2007; 156: 945-950.

– Krueger G G, Langley R G, Leonardi C, Yeilding N, Guzzo C, Wang Y, Dooley L T, Lebwhohl M.  A human interleukin-12/23 Monoclonal antibody for the treatment of psoriasis.  N Engl J Med 2007; 356(6): 580-592.

– Mazharinia N, Aghaei S, Shayan Z. Dermatology Life Quality Index (DLQI) scores in burn victims after revivalJ Burn Care Res 2007; 28(2): 312 – 317.

– Misery L, Finlay A Y, Martin N, Boussetta S, Nguyen C, Myon E, Taieb C.Atopic dermatitis: impact on the quality of life of patients and their partnersDermatology 2007; 215(2): 123 – 129.

– Moore A, Gordon K B, Kang S, Gottlieb A, Freundlich B, Xia H A, Stevens S R.  A randomized, open-label trial of continuous versus interrupted etanercept therapy in the treatment of psoriasis.  J am Acad Dermatol2007; 56(4): 598-603.

– Mozaffari H, Pourpack Z, Pourseyed S, Farhoodi A, Aghamohammadi A, Movahadi M, Gharaghozloom, Moin M. Quality of lie in atopic dermatitis patientsJ Microbiol Immunol Infect 2007; 40(3): 260-264.

– Nijsten T, Mweads D M, de Korte J, Sampogna F, Gelfand J M, Ongenae K, Evers A W, Augustin M. Cross- cultural inequivalence of dermatology- specific health- related quality of life instruments in psoriasis patients.J Invest Dermatol 2007; May (E-pub).

– Oppel T, Pavicic T, Kamann S, Bräutigam M, Wollenberg A.Pimecrolimus cream (1%) efficacy in perioral dermatitis – results of a randomized, double-blind, vehicle-controlled study in 40 patients.J Eur Acad Dermatol Venereol.2007 Oct;21(9):1175-80.

– Papoutsaski M, Chimenti M S, Costanzo A, Talamonti M, Zangrilli A, Giuta A, Bianchi L, Chimenti S. Adalimumab for severe psoriasis and psoriatic arthritis: an open label study in 30 patients previously treated with other biologics.J Am Acad Dermatol 2007; 56(2): 269- 275.

– Reich K, Nestle F O, Wu Y, Bala M, Eiseberg D, Guzzo C, Li S, Dooley L T, Griffiths C E. Infliximab treatment improves productivity among patient with moderate – severe psoriasisEur J Dermatol 2007; 17(5): 381 – 386.

– Rhee J S, Matthews B A, Neuburg M, Logan B R, Burzynski M, Nattinger A B. The skin cancer index: clinical responsiveness and predictors of quality of lifeLaryngoscope 2007; 117(3): 399 – 405.

– Salek S, Roberts A, Finlay AY. The practical reality of using a patient-reported outcome measure in a routine dermatology clinic.Dermatology. 2007; 215(4):315-9.

– Sampogna F, Gisondi P, Tabolli S, Abeni D & the IDI Multipurpose Psoriasis Research on Vital Experiences investigations.  Impairment of sexual life in patients with psoriasis.Dermatology 2007; 214: 144-150.

– Schmitt J M, Ford D E.  Role of depression in quality of life for patients with psoriasis.  Dermatology 2007; 215: 17-27.

– Schmitt J, Heese E, Wozel G, Meurer M.  Effectiveness of inpatient treatment on quality of life and clinical disease severity in atopic dermatitis and psoriasis vulgaris – a prospective study.  Dermatology2007; 214: 68-76.

– Schmitt-Egenolf M.  PsoReg – The Swedish registry for systemic psoriasis treatment.Dermatology 2007; 214: 112-117.

– Schöffski O, Augustin M, Prinz J, Runder K, Schubert E, Sohn S, Reich K. Cost and quality of life in patients with moderate to severe plaque- type psoriasis in Germany: a multi- centre study (Article in German)J Dtsch Dermatol Ges 2007; 5(3): 209 – 218.

– Shikiar R, Heffernan M, Langley R G, Willian M K, Okun M M, Revicki D A.  Adalimumab treatment is associated with improvement in health-related quality of life in psoriasis:  Patient-reported outcomes from a Phase II randomized controlled trial.  J Dermatol Treat 2007; 18: 25-31.

– Spector S L, Shikiar R, Harding G, Meeves S, Leahy M J. The effect of fexofenadine hydrochloride on productivity and quality of life in patients with chronic idiopathic urticariaCutis 2007; 79(2): 157 – 162.

– Tyring S, Kenneth B, Gordon M D, Poulin Y, Langley R, Gordon K, Gottlieb A, Dunn M, Jahreis A.  Long-term safety and efficacy of 50 mg etanercept twice weekly in patients with psoriasis.  Arch Dermatol2007; 143: 719-723.

– Weatherhead S C, Wahie S, Reynolds N J, Meggitt S J.  An open-label, dose-ranging study of methotrexate for moderate-to-severe adult atopic eczema.  Br J Dermatol 2007; 156: 346-351.

– Yones S S, Palmer R A, Garibaldinos T M, John R N, Hawk L M. Randomized double-blind trial of treatment of vitiligo.  Arch Dermatol2007; 143: 578-584.

2008

– Agner T, Andersen KE, Brandao FM, Bruynzeel DP, Bruze M, Frosch P, Goncalo M, Goossens A, Le Coz CJ, Rustemeyer T, White IR, Diepgen T; EECDRG.
Hand eczema severity and quality of life: a cross-sectional, multicentre study of hand eczema patients.
Contact Dermatitis. 2008 Jul;59(1):43-7. Epub 2008 Jul 1.

– Ali R, Burns P, Donnelly M. Otitis externa: quality of life assessment.Ir J Med Sc 2008; 177: 221-3.

– Amini M, Harmsze AM, Tupker RA.
Patient’s estimation of efficacy of various hyperhidrosis treatments in a dermatological clinic.
Acta Derm Venereol. 2008;88(4):356-62.

– Ammad S, Gonzales M, Edwards C, Finlay AY, Mills C.
An assessment of the efficacy of blue light phototherapy in the treatment of acne vulgaris.
Cosmet Dermatol. 2008 Sep;7(3):180-8.

– Augustin M, Gajur A I, Rustenbach S J, Schaefer I.  Benefit evaluation in vitiligo treatment:  development and validation of a patient-defined outcome questionnaire.  Dermatology 2008; 217: 101-106.

– Augustin M, Krüger K, Radtke MA, Schwippl I, Reich K.
Disease severity, quality of life and health care in plaque-type psoriasis: a multicenter cross-sectional study in Germany.
Dermatology. 2008;216(4):366-72. Epub 2008 Mar 4.

– Augustin M, Reich K, Reich C, Purwins S, Jeff Rustenbach S, Schäfer I, Radtke M.
Quality of psoriasis care in Germany–results of the national study PsoHealth 2007. [Article in English, German]
J Dtsch Dermatol Ges. 2008 Aug;6(8):640-5.

– Basra M K A, Edmunds O, Salek M S, Finlay A Y.  Measurement of family impact of skin disease:  further validation of the Family Dermatology Life Quality Index (FDLQI).J Eur Acad Dermatol Venereol2008; 22: 813-821.

– Basra MK, Fenech R, Gatt RM, Salek MS, Finlay AY.
The Dermatology Life Quality Index 1994-2007: a comprehensive review of validation data and clinical results.
Br J Dermatol. 2008 Nov;159(5):997-1035. Epub 2008 Sep 15.

– Bechara FG, Gambichler T, Brockmeyer NH, Sand M, Altmeyer P, Hoffmann K.
Hyaluronic acid new formulation: experience in HIV-associated facial lipoatrophy.
Dermatology. 2008;217(3):244-9. Epub 2008 Jul 25.

– Bender B G, Ballard R, Canono B, Murphy RJ R, Leung D Y M.  Disease severity, scratching and sleep quality of patients with atopic dermatitis.  J Am Acad Dermatol 2008; 58: 415-420.

– Carroll C L, Lang W, Snively B, Feldman S R, Callen J, Jorizzo  J L. Development and validation of the Dermatomyositis Skin Severity Index.  Br J Dermatol 2008; 158:
345-350.

– Chang CC, Gangaram HB, Hussein SH.
Malaysian Psoriasis Registry–preliminary report of a pilot study using a newly revised registry form.
Med J Malaysia. 2008 Sep;63 Suppl C:68-71.

– Colombo G, Altomare G, Peris K, Martini P, Quarta G, Congedo M, Costanzo A, Di Cesare A, Lapucci E, Chimenti S.
Moderate and severe plaque psoriasis: cost-of-illness study in Italy.
Ther Clin Risk Manag. 2008 Apr;4(2):559-68.

– Davarian S, Kalantari KK, Rezasoltani A, Rahimi A.
Effect and persistency of botulinum toxin iontophoresis in the treatment of palmar hyperhidrosis.
Australas J Dermatol. 2008 May;49(2):75-9.

– Davies E, Patel C, Salek M S, Finlay A Y.  Does ad hoc quality of life discussion in inflammatory skin disease consultations reflect standardized patient-reported outcomes?  Clinical & Experimental Dermatology 2008; 33: 16-21.

– De Rauglaudre G, Courdi A, Delaby-Chagrin F, d’Hombres A, Hannoun-Levi JM, Moureau-Zabotto L, Richard-Tallet A, Rouah Y, Salem N, Thomas O, Nocera T, Mery S, Merial-Kieny C. [Tolerance of the association sucralfate / Cu-Zn salts in radiation dermatitis].Ann Dermatol Venereol2008; Spec No 1:11-5. [Article in French]

– Drouin R, Moroni O, Cantin K, Juneau C.
A double-blind, placebo-controlled, randomized trial of XP-828L (800 mg) on the quality of life and clinical symptoms of patients with mild-to-moderate psoriasis.
Altern Med Rev. 2008 Jun;13(2):145-52.

– Feldman SR, Gottlieb AB, Bala M, Wu Y, Eisenberg D, Guzzo C, Li S, Dooley LT, Menter A.
Infliximab improves health-related quality of life in the presence of comorbidities among patients with moderate-to-severe psoriasis.
Br J Dermatol. 2008 Sep;159(3):704-10. Epub 2008 Jul 9.

– Flyström I, Stenberg B, Svensson Å, Bergbrant I-M.  Methotrexate vsciclosporin in psoriasis:  effectiveness, quality of life and safety.  A randomized controlled trial.  Br J Dermatol 2008; 158: 116-121.

– Gelfand JM, Kimball AB, Mostow EN, Chiou CF, Patel V, Xia HA, Freundlich B, Stevens SR.
Patient-reported outcomes and health-care resource utilization in patients with psoriasis treated with etanercept: continuous versus interrupted treatment.
Value Health. 2008 May-Jun;11(3):400-7.

– Gokdemir G, Ari S, Köşlü A.  Adherence to treatment in patients with psoriasis vulgaris:  Turkish experience.  JEADV 2008; 22: 330-335.

– Grob J J, Auquier P, Dreyfus I, Ortonne J P.  Quality of life in adults with chronic idiopathic urticaria receiving Desloratadine:  a randomized, double-blind, multicentre, placebo-controlled study.  JEADV 2008 22: 87-93.

– Gupta AK, Langley RG, Lynde C, Barber K, Gulliver W, Lauzon G, Aspeslet LJ, Foster RT, Huizinga RB, Yatscoff RW.
ISA247: quality of life results from a phase II, randomized, placebo-controlled study.
J Cutan Med Surg. 2008 Nov-Dec;12(6):268-75.

– Hartmann A, Bröcker EB, Hamm H.
Occlusive treatment enhances efficacy of tacrolimus 0.1% ointment in adult patients with vitiligo: results of a placebo-controlled 12-month prospective study.
Acta Derm Venereol. 2008;88(5):474-9.

– Henok L, Davey G.
Validation of the Dermatology Life Quality Index among patients with podoconiosis in southern Ethiopia.
Br J Dermatol. 2008 Sep;159(4):903-6. Epub 2008 Jul 30.

– Jacobi A, Braeutigam M, Mahler V, Schultz E, Hertl M.  Pimecrolimus 1% cream in the treatment of facial psoriasis:   A 16 week open-label study.  Dermatology 2008; 216: 133-136.

– Jong CT, Finlay AY, Pearse AD, Kerr AC, Ferguson J, Benton EC, Hawk JL, Sarkany RP, McMullen E, Rhodes LE, Farr PM, Anstey AV.
The quality of life of 790 patients with photodermatoses.
Br J Dermatol. 2008 Jul;159(1):192-7. Epub 2008 Jul 1.

– Kaymak Y, Taner E.
Anxiety and depression in patients with pityriasis rosea compared to patients with tinea versicolor.
Dermatol Nurs. 2008 Oct;20(5):367-70, 377.

– Kieć-Swierczyńska M, Krecisz B, Potocka A, Swierczyńska-Machura D, Dudek W, Pałczyński C.
[Psychological factors in allergic skin diseases] [Article in Polish]
Med Pr. 2008;59(4):279-85.

– Kircik L, Bagel J, Korman N, Menter A, Elmets CA, Koo J, Yang YC, Chiou CF, Dann F, Stevens SR; Unite Study Group.
Utilization of narrow-band ultraviolet light B therapy and etanercept for the treatment of psoriasis (UNITE): efficacy, safety, and patient-reported outcomes.
J Drugs Dermatol. 2008 Mar;7(3):245-53.

– Kulthanan K, Chiawsirikajorn Y, Jiamton S.
Acute urticaria: etiologies, clinical course and quality of life.
Asian Pac J Allergy Immunol. 2008 Mar;26(1):1-9.

– Le Cleach L, Chassany O, Levy A, Wolkenstein P, Chosidow O. Poor Reporting of Quality of Life Outcomes in Dermatology Randomized Controlled Clinical TrialsDermatology 2008; 216: 46 – 55

– Li FL, Li B, Xu R, Song X, Yu Y, Xu ZC.
[Qinzhu Liangxue Decoction in treatment of blood-heat type psoriasis vulgaris: a randomized controlled trial] [Article in Chinese]
Zhong Xi Yi Jie He Xue Bao. 2008 Jun;6(6):586-90.

– Liu Z-H, Du X-H.  Quality of life in patients with facial steroid dermatitis before and after treatment.  JEADV 2008; 22: 663-669.

– Lloyd A, Reeves P, Conway P, Reynolds A, Baxter G. Economic evaluation of etanercept in the management of chronic plaque psoriasisBr J Dermatol 2008 (early online).

– Mekkes J R, Bos J D.  Long-term efficacy of a single course of infliximab in hidradenitis suppurativa.  Br J Dermatol 2008; 158: 370-374.

– Młynek A, Zalewska-Janowska A, Martus P, Staubach P, Zuberbier T, Maurer M.
How to assess disease activity in patients with chronic urticaria?
Allergy. 2008 Jun;63(6):777-80.

– Mraz S, Leonardi C, Colón LE, Johnson LA.
Different treatment outcomes with different formulations of clobetasol propionate 0.05% for the treatment of plaque psoriasis.
J Dermatolog Treat. 2008;19(6):354-9.

– Nelson A A, Pearce D J, Fleischer A B, Balkrishnan R, Feldman S R. Cost-effectiveness of biologic treatments for psoriasis based on subjective and objective efficacy measures assessed over a 12-week treatment period.  J Am Acad Dermatol 2008; 58: 125-135.

– Nienhaus A, Kromark K, Raulf-Heimsoth M, van Kampen V, Merget R.
Outcome of occupational latex allergy–work ability and quality of life.
PLoS One. 2008;3(10):e3459. Epub 2008 Oct 21.

– Panahi Y, Davoudi SM, Sadr SB, Naghizadeh MM, Mohammadi-Mofrad M.
Impact of pruritus on quality of life in sulfur mustard-exposed Iranian veterans.
Int J Dermatol. 2008 Jun;47(6):557-61.

– Peserico A, Städtler G, Sebastian M, Fernandez R S, Vick K, Bieber T. Reduction of relapses of atopic dermatitis with methylprednisolone aceponate cream twice weekly in addition to maintenance treatment with emollient:  a multicentre, randomized, double-blind, controlled study.  Br J Dermatol 2008; 158: 801-807.

– Potocka A, Turczyn-Jabłońska K, Kieć-Swierczyńska M.
Self-image and quality of life of dermatology patients.
Int J Occup Med Environ Health. 2008;21(4):309-17.

– Quandt SA, Schulz MR, Vallejos QM, Feldman SR, Preisser JS, Arcury TA.
Skin-related quality of life among migrant farmworkers.
J Cutan Med Surg. 2008 Jan-Feb;12(1):1-7.

– Quandt S A, Schulz M R, Vallejos Q M, Feldman S R, Verma A, Fleischer A B, Rapp S R, Arcury T A..  The association of dermatologist-diagnosed and self-reported skin diseases with skin-related quality of life in Latino migrant farm workers.   Int J Dermatol 2008; 47: 236-241.

– Reich K, Griffiths CE.
The relationship between quality of life and skin clearance in moderate-to-severe psoriasis: lessons learnt from clinical trials with infliximab.
Arch Dermatol Res. 2008 Nov;300(10):537-44. Epub 2008 Sep 11.

– Reich K, Sinclair R, Roberts G, Griffiths CE, Tabberer M, Barker J.
Comparative effects of biological therapies on the severity of skin symptoms and health-related quality of life in patients with plaque-type psoriasis: a meta-analysis.
Curr Med Res Opin. 2008 May;24(5):1237-54. Epub 2008 Mar 19.

– Revicki DA, Willian MK, Menter A, Gordon KB, Kimball AB, Leonardi CL, Langley RG, Kimel M, Okun M.
Impact of adalimumab treatment on patient-reported outcomes: results from a Phase III clinical trial in patients with moderate to severe plaque psoriasis.
J Dermatolog Treat. 2007;18(6):341-50.

– Revicki DA, Willian MK, Menter A, Saurat JH, Harnam N, Kaul M.
Relationship between clinical response to therapy and health-related quality of life outcomes in patients with moderate to severe plaque psoriasis.
Dermatology. 2008;216(3):260-70. Epub 2008 Jan 11.

– Revicki D, Willian M K, Saurat J-H, Papp K A, Ortonne J-P, Sexton C, Camez A.  Impact of adalimumab treatment on health-related quality of life and other patient-reported outcomes:  results from a 16-week randomized controlled trial in patients with moderate to severe plaque psoriasis.  Br J Dermatol 2008; 158: 549-557.

– Richards H L, Ling T C, Evangelou G, Brooke R C C, Fortune D G, Rhodes L E.  Evidence of high levels of anxiety and depression in polymorphic light eruption and their association with clinical and demographic variables.  Br J Dermatol 2008; 159: 439-444.

– Salameh F, Perla D, Solomon M, Gamus D, Barzilai A, Greenberger S, Trau H.
The effectiveness of combined Chinese herbal medicine and acupuncture in the treatment of atopic dermatitis.
J Altern Complement Med. 2008 Oct;14(8):1043-8.

– Schmitt J, Meurer M, Klon M Frick K D.  Assessment of health state utilities of controlled and uncontrolled psoriasis and atopic eczema:  a population-based study.   Br J Dermatol 2008; 158: 351-359.

– Schwarz T, Kreiselmaier I, Bieber T, Thaci D, Simon J C, Meurer M, Werfel T, Zuberbier T, Luger T A, Wollenberg A, Brautigam M.  A randomized, double-blind, vehicle-controlled study of 1% pimecrolimus cream in adult patients with perioral dermatitis.  J Am Acad Dermatol 2008; 59 (1): 34-40.
Semenou D, Cœugniet E, Senard M, Martinot-Duquennoy V, Delaporte E.Launois-Bensaude’s disease: report of 17 cases. [Article in French].Ann Chir Plast Esthet. 2007; 53: 399-407.
Sinclair W, Aboobaker J, Jordaan F, Modi D, Todd G.
Management of atopic dermatitis in adolescents and adults in South Africa.
S Afr Med J. 2008 Apr;98(4 Pt 2):303-19.

– Szepietowski JC, Reich A, Wesołowska-Szepietowska E, Baran E; for the National Quality of Life in Dermatology Group.
Quality of life in patients suffering from seborrheic dermatitis: influence of age, gender and education level.
Mycoses. 2008 Sep 12. [Epub ahead of print]

– Tribó MJ, Andión O, Ros S, Gilaberte M, Gallardo F, Toll A, Ferrán M, Bulbena A, Pujol RM, Baños JE.
Clinical characteristics and psychopathological profile of patients with vulvodynia: an observational and descriptive study.
Dermatology. 2008;216(1):24-30.

– Vilata JJ, Varela JA, Olmos L, Colombo JA, Llorens MA, de los Terreros MS, Badía X; ECCAVIM Study Group.
Validation and clinical use of the CECA, a disease-specific quality of life questionnaire for patients with anogenital condylomata acuminata.
Acta Derm Venereol. 2008;88(3):257-62.

– Wakkee M, Thio H B, Spuls P I, De Jong E M, Nijsten T.  Evaluation of the reimbursement criteria for biological therapies for psoriasis in the Netherlands.  Br J Dermatol 2008; 158: 1159-1161.

– Woods A L, Rutter K J, Gardner L S, Lewis V J, Saxena S, George S A, Chalmers R J G, Griffiths C E M, Speight E L, Anstey A V, Ronda L, McGibbon D, Barker J W N, Smith C H.  Inpatient management of psoriasis:  a multicentre service review to establish national admission standards.  Br J Dermatol 2008; 158: 266-272.

– Zachariae R, Zachariae C O C, Lei U, Pedersen A F.  Affective and sensory dimensions of pruritus severity:  associations with psychological symptoms and quality of life in psoriasis patients.  Acta Derm Venereol 2008; 88: 121-127.

– Zangrilli A, Papoutsaki M, Talamonti M, Chimenti S.
Long-term efficacy of adalimumab in generalized pustular psoriasis.

– J Dermatolog Treat. 2008;19(3):185-7.

2009

– Abdel-Hafez K, Mahran AM, Hofny ER, Mohammed KA, Darweesh AM, Aal AA.
The impact of acne vulgaris on the quality of life and psychologic status in patients from upper Egypt.
Int J Dermatol. 2009 Mar;48(3):280-5.

– Aghaei S, Moradi A, Ardekani GS.
Impact of psoriasis on quality of life in Iran.
Indian J Dermatol Venereol Leprol. 2009 Mar-Apr;75(2):220.

– Agner T, Andersen KE, Brandao FM, Bruynzeel DP, Bruze M, Frosch P, Gonçalo M, Goossens A, Le Coz CJ, Rustemeyer T, White IR, Diepgen T; EECDRG.
Contact sensitisation in hand eczema patients-relation to subdiagnosis, severity and quality of life: a multi-centre study.
Contact Dermatitis. 2009 Nov;61(5):291-6.

– Ambrogi V, Campione E, Mineo D, Paternò EJ, Pompeo E, Mineo TC.
Bilateral thoracoscopic T2 to T3 sympathectomy versus botulinum injection in palmar hyperhidrosis.
Ann Thorac Surg. 2009 Jul;88(1):238-45.

– Balci DD, Inandi T, Dogramaci CA, Celik E.
DLQI scores in patients with keloids and hypertrophic scars: a prospective case control study. [Article in English, German]
J Dtsch Dermatol Ges. 2009 Aug;7(8):688-92. Epub 2009 Feb 18.

– Bangsgaard N, Marckmann P, Rossen K, Skov L.
Nephrogenic systemic fibrosis: late skin manifestations.
Arch Dermatol. 2009 Feb;145(2):183-7.

– Bilac C, Ermertcan AT, Bilac DB, Deveci A, Horasan GD.
The relationship between symptoms and patient characteristics among psoriasis patients.
Indian J Dermatol Venereol Leprol. 2009 Sep-Oct;75(5):551.

– Blanco R, Martínez-Taboada VM, Villa I, González-Vela MC, Fernández-Llaca H, Agudo M, González-López MA.
Long-term successful adalimumab therapy in severe hidradenitis suppurativa.
Arch Dermatol. 2009 May;145(5):580-4.

– Brunasso A M G, Salvini C, Massone C. Efalizumab for severe palmo-plantar psoriasis:  an open-label pilot trial in five patients.  JEADV2009; 23: 415-419.

– Bygum A, Andersen KE, Mikkelsen CS.
Self-administration of intravenous C1-inhibitor therapy for hereditary angioedema and associated quality of life benefits.
Eur J Dermatol. 2009 Mar-Apr;19(2):147-51.

– Campanati A, Goteri G, Simonetti O, Ganzetti G, Giuliodori K, Giuliano A, Sabato S, Stramazzotti D, Gulini E, Dusi D, De Blasio S, Fabris G, Offidani A.
Angiogenesis in psoriatic skin and its modifications after administration of etanercept: videocapillaroscopic, histological and immunohistochemical evaluation.
Int J Immunopathol Pharmacol. 2009 Apr-Jun;22(2):371-7.

– Cartwright T, Endean N, Porter A.
Illness perceptions, coping and quality of life in patients with alopecia.
Br J Dermatol. 2009 May;160(5):1034-9. Epub 2009 Jan 20.

– Chernyshov PV.
[Creation and cross-cultural adaptation of the Ukrainian versions of SKINDEX-29, SKINDEX-16 questionnaires, Psoriasis Disability Index and further validation of the Ukrainian version of the Dermatology Life Quality Index][Article in Ukrainian]
Lik Sprava. 2009 Jan-Feb;(1-2):95-8.

– Daudén E, Griffiths CE, Ortonne JP, Kragballe K, Molta CT, Robertson D, Pedersen R, Estojak J, Boggs R.
Improvements in patient-reported outcomes in moderate-to-severe psoriasis patients receiving continuous or paused etanercept treatment over 54 weeks: the CRYSTEL study.
J Eur Acad Dermatol Venereol. 2009 Dec;23(12):1374-82. Epub 2009 Jun 26.

– Dawn A, Papoiu AD, Chan YH, Rapp SR, Rassette N, Yosipovitch G.
Itch characteristics in atopic dermatitis: results of a web-based questionnaire.
Br J Dermatol. 2009 Mar;160(3):642-4. Epub 2008 Nov 25.

– Dolatshahi M, Ghazi P, Feizy V, Hemami MR.
Life quality assessment among patients with vitiligo: comparison of married and single patients in Iran.
Indian J Dermatol Venereol Leprol. 2008 Nov-Dec;74(6):700.

– Eghlileb AM, Basra MK, Finlay AY.
The psoriasis family index: preliminary results of validation of a quality of life instrument for family members of patients with psoriasis.
Dermatology. 2009;219(1):63-70. Epub 2009 Mar 13.

– Evers A W M, Duller P, De Jong  E M G J, Otero M E, Verhaak C M, Van Der Valk P G M, Van D Kerkhof P C M & Kraaimaat F W.  Effectiveness of a multidisciplinary itch-coping training programme in adults with atopic dermatitis.  Acta Derm Venereol 2009; 89: 57-63.

– Grob JJ, Auquier P, Dreyfus I, Ortonne JP.
How to prescribe antihistamines for chronic idiopathic urticaria: desloratadine daily vs PRN and quality of life.
Allergy. 2009 Apr;64(4):605-12. Epub 2008 Dec 30.

– Hickerson RP, Leake D, Pho LN, Leachman SA, Kaspar RL.
Rapamycin selectively inhibits expression of an inducible keratin (K6a) in human keratinocytes and improves symptoms in pachyonychia congenita patients.
J Dermatol Sci. 2009 Nov;56(2):82-8. Epub 2009 Aug 21.

– Huggins RH, Leithauser LA, Eide MJ, Hexsel CL, Jacobsen G, Lim HW.
Quality of life assessment and disease experience of patient members of a web-based hydroa vacciniforme support group.
Photodermatol Photoimmunol Photomed. 2009 Aug;25(4):209-15.

– Idriss S Z, Kvedr J C, Watson A J.  The role of online support communities.  Arch Dermatol  2009; 145: 46-51.

– Jariwala SP, Moday H, de Asis ML, Fodeman J, Hudes G, de Vos G, Rosenstreich D.
The Urticaria Severity Score: a sensitive questionnaire/index for monitoring response to therapy in patients with chronic urticaria.
Ann Allergy Asthma Immunol. 2009 Jun;102(6):475-82.

– Joshi SS, Boone SL, Alam M, Yoo S, White L, Rademaker A, Helenowski I, West DP, Kundu RV.
Effectiveness, safety, and effect on quality of life of topical salicylic acid peels for treatment of postinflammatory hyperpigmentation in dark skin.
Dermatol Surg. 2009 Apr;35(4):638-44.

– Kaymak Y, Taner E, Taner Y.
Comparison of depression, anxiety and life quality in acne vulgaris patients who were treated with either isotretinoin or topical agents.
Int J Dermatol. 2009 Jan;48(1):41-6.

– Katsambas A, Peris K, Vena G, Freidmann P, Wozel G, Daudén E, Licu D, Placchi M, De La Brassinne M.
Assessing the Impact of Efalizumab on Nail, Scalp and Palmoplantar Psoriasis and on Quality of Life: Results from a Multicentre, Open-label, Phase IIIb/IV Trial.
Arch Drug Inf. 2009 Dec;2(4):66-70.

– Keating GM.
Human C1-esterase inhibitor concentrate (Berinert).
BioDrugs. 2009;23(6):399-406. doi: 10.2165/11201100-000000000-00000.

– Kim WO, Kil HK, Yoon KB, Noh KU.
Botulinum toxin: a treatment for compensatory hyperhidrosis in the trunk.
Dermatol Surg. 2009 May;35(5):833-8; discussion 838. Epub 2009 Mar 30.

– Kinahan KE, Gandhi M, Lacouture ME, Eilers R Jr, Haryani A, Didwania A, Sharp LK.
Dermatologic issues in adult survivors of childhood cancer.
J Cancer Surviv. 2009 Sep;3(3):158-63. Epub 2009 May 28.

– Kircik LH.
Observational evaluation of sertaconazole nitrate cream 2% in the treatment of pruritus related to tinea pedis.
Cutis. 2009 Nov;84(5):279-83.

– Kobayashi M, Kabashima K, Nakamura M, Tokura Y.
Effects of oral antibiotic roxithromycin on quality of life in acne patients.
J Dermatol. 2009 Jul;36(7):383-91.

– Kostopoulou P, Jouary T, Quintard B, Ezzedine K, Marques S, Boutchnei S, Taieb A.
Objective vs. subjective factors in the psychological impact of vitiligo: the experience from a French referral centre.
Br J Dermatol. 2009 Jul;161(1):128-33. Epub 2009 Mar 9.

– Lee RA, Dommasch E, Treat J, Sciacca-Kirby J, Chachkin S, Williams J, Shin DB, Leyden JJ, Vittorio C, Gelfand JM.
A prospective clinical trial of open-label etanercept for the treatment of hidradenitis suppurativa.
J Am Acad Dermatol. 2009 Apr;60(4):565-73. Epub 2009 Jan 31.

– Lloyd A, Reeves P, Conway P, Reynolds A, Baxter G.
Economic evaluation of etanercept in the management of chronic plaque psoriasis.
Br J Dermatol. 2009 Feb;160(2):380-6. Epub 2008 Sep 19.

– Loveman E, Turner D, Hartwell D, Cooper K, Clegg A.
Infliximab for the treatment of adults with psoriasis.
Health Technol Assess. 2009 Jun;13 Suppl 1:55-60.

– Ludwig MW, Oliveira Mda S, Muller MC, Moraes JF.
Quality of life and site of the lesion in dermatological patients.
[Article in English, Portuguese]
An Bras Dermatol. 2009 Mar-Apr;84(2):143-50.

– Luger TA, Barker J, Lambert J, Yang S, Robertson D, Foehl J, Molta CT, Boggs R.
Sustained improvement in joint pain and nail symptoms with etanercept therapy in patients with moderate-to-severe psoriasis.
J Eur Acad Dermatol Venereol. 2009 Aug;23(8):896-904. Epub 2009 May 3.

– Martyn-Simmons CL, Green L, Ash G, Groves RW, Smith CH, Barker JN.
Adalimumab for psoriasis patients who are non-responders to etanercept: open-label prospective evaluation.
J Eur Acad Dermatol Venereol. 2009 Dec;23(12):1394-7. Epub 2009 Jul 1.

– Menezes N, Moreira A, Mota G, Baptista A.
Quality of life and rosacea: pulsed dye laser impact.
J Cosmet Laser Ther. 2009 Sep;11(3):139-41.

– Młynek A, Magerl M, Hanna M, Lhachimi S, Baiardini I, Canonica GW, Brzoza Z, Kasperska-Zajac A, Rogala B, Zalewska-Janowska A, Zuberbier T, Maurer M.
The German version of the Chronic Urticaria Quality-of-Life Questionnaire: factor analysis, validation, and initial clinical findings.
Allergy. 2009 Jun;64(6):927-36.

– Mühleisen B, Büchi S, Schmidhauser S, Jenewein J, French LE, Hofbauer GF.
Pictorial Representation of Illness and Self Measure (PRISM): A novel visual instrument to measure quality of life in dermatological inpatients.
Arch Dermatol. 2009 Jul;145(7):774-80.

– Osio A, Mateus C, Soria JC, Massard C, Malka D, Boige V, Besse B, Robert C.
Cutaneous side-effects in patients on long-term treatment with epidermal growth factor receptor inhibitors.
Br J Dermatol. 2009 Sep;161(3):515-21. Epub 2009 Apr 10.

– Peeters M, Siena S, Van Cutsem E, Sobrero A, Hendlisz A, Cascinu S, Kalofonos H, Devercelli G, Wolf M, Amado RG.
Association of progression-free survival, overall survival, and patient-reported outcomes by skin toxicity and KRAS status in patients receiving panitumumab monotherapy.
Cancer. 2009 Apr 1;115(7):1544-54.

– Pichardo R, Vallejos Q, Feldman SR, Schulz MR, Verma A, Quandt SA, Arcury TA.
The prevalence of melasma and its association with quality of life in adult male Latino migrant workers.
Int J Dermatol. 2009 Jan;48(1):22-6.

– Potocka A, Turczyn-Jabloñska K, Merecz D.
Psychological correlates of quality of life in dermatology patients: the role of mental health and self-acceptance.
Acta Dermatovenerol Alp Panonica Adriat. 2009 Jun;18(2):53-8, 60, 62.

– Radtke MA, Reich K, Blome C, Kopp I, Rustenbach SJ, Schäfer I, Augustin M.
Evaluation of quality of care and guideline-compliant treatment in psoriasis. Development of a new system of quality indicators.
Dermatology. 2009;219(1):54-8. Epub 2009 May 7.

– Radtke MA, Schäfer I, Gajur A, Langenbruch A, Augustin M.
Willingness-to-pay and quality of life in patients with vitiligo.
Br J Dermatol. 2009 Jul;161(1):134-9. Epub 2009 Mar 9.

– Reich K, Krüger K, Mössner R, Augustin M.
Epidemiology and clinical pattern of psoriatic arthritis in Germany: a prospective interdisciplinary epidemiological study of 1511 patients with plaque-type psoriasis.
Br J Dermatol. 2009 May;160(5):1040-7. Epub 2009 Feb 4.

– Reich K, Segaert S, Van de Kerkhof P, Durian C, Boussuge MP, Paolozzi L, Wajdula J, Boggs R.
Once-weekly administration of etanercept 50 mg improves patient-reported outcomes in patients with moderate-to-severe plaque psoriasis.
Dermatology. 2009;219(3):239-49. Epub 2009 Sep 10.

– Saccomani C, Penz S, Guerre-Schmidt R, Riou MO, Pelletier F, Puzenat E, Mermet I, Levang J, Humbert P, Aubin F.
[Biological therapy for psoriasis: practical experience at a French dermatology unit]
[Article in French]
Ann Dermatol Venereol. 2009 Dec;136(12):877-82.

– Sartorius K, Emtestam L, Jemec GB, Lapins J.
Objective scoring of hidradenitis suppurativa reflecting the role of tobacco smoking and obesity.
Br J Dermatol. 2009 Oct;161(4):831-9. Epub 2009 Apr 29.

– Scanlon JV, Exter BP, Steinberg M, Jarvis CI.
Ustekinumab: treatment of adult moderate-to-severe chronic plaque psoriasis.
Ann Pharmacother. 2009 Sep;43(9):1456-65. Epub 2009 Aug 11.

– Spelt JM, de Rooij FW, Wilson JH, Zandbergen AA.
Vitamin D deficiency in patients with erythropoietic protoporphyria.
J Inherit Metab Dis. 2009 Jan 10. [Epub ahead of print]

– Tan J, Thomas R, Wang B, Gratton D, Vender R, Kerrouche N, Villemagne H; CalePso Study Team.
Short-contact clobetasol propionate shampoo 0.05% improves quality of life in patients with scalp psoriasis.
Cutis. 2009 Mar;83(3):157-64.

– Tetteh HA, Groth SS, Kast T, Whitson BA, Radosevich DM, Klopp AC, D’Cunha J, Maddaus MA, Andrade RS.
Primary palmoplantar hyperhidrosis and thoracoscopic sympathectomy: a new objective assessment method.
Ann Thorac Surg. 2009 Jan;87(1):267-74; discussion 274-5.

– Tiplica GS, Salavastru CM.
Mometasone furoate 0.1% and salicylic acid 5% vs. mometasone furoate 0.1% as sequential local therapy in psoriasis vulgaris.
J Eur Acad Dermatol Venereol. 2009 Aug;23(8):905-12. Epub 2009 Mar 11.

– Warren RB, Brown BC, Lavery D, Ashcroft DM, Griffiths CE.
Biologic therapies for psoriasis: practical experience in a U.K. tertiary referral centre.
Br J Dermatol. 2009 Jan;160(1):162-9. Epub 2008 Sep 19.

– Wasel N, Poulin Y, Andrew R, Chan D, Fraquelli E, Papp K.
A Canadian self-administered online survey to evaluate the impact of moderate-to-severe psoriasis among patients.
J Cutan Med Surg. 2009 Nov-Dec;13(6):294-302.

– Weber J, Keam SJ.
Ustekinumab.
BioDrugs. 2009;23(1):53-61. doi: 10.2165/00063030-200923010-00006.

– Wolkenstein P, Rodriguez D, Ferkal S, Gravier H, Buret V, Algans N, Simeoni MC, Bastuji-Garin S.
Impact of neurofibromatosis 1 upon quality of life in childhood: a cross-sectional study of 79 cases.

–  Br J Dermatol. 2009 Apr;160(4):844-8. Epub 2008 Dec 5.

2010

– Adams DR, Yankura JA, Fogelberg AC, Anderson BE.
Treatment of hidradenitis suppurativa with etanercept injection.
Arch Dermatol. 2010 May;146(5):501-4.

– Akaraphanth R, Kittipavara Y, Voravutinon N, Wachiratarapadorn U, Gritiyarangsan P.
Efficacy of a far erythemogenic dose of narrow-band ultraviolet B phototherapy in chronic plaque-type psoriasis.
J Dermatol. 2010 Feb;37(2):140-5.

– Aksoy B, Altaykan-Hapa A, Egemen D, Karagöz F, Atakan N.
The impact of rosacea on quality of life: effects of demographic and clinical characteristics and various treatment modalities.
Br J Dermatol. 2010 Oct;163(4):719-25.

– Amano M, Grant A, Kerdel FA.
A prospective open-label clinical trial of adalimumab for the treatment of hidradenitis suppurativa.
Int J Dermatol. 2010 Aug;49(8):950-5.

– An JG, Ma JH, Xiao SX, Xiao SB, Yang F.
Quality of life in patients with lepromatous leprosy in China.
J Eur Acad Dermatol Venereol. 2010 Jul;24(7):827-32.

– Antoniou C, Stefanaki I, Stratigos A, Moustou E, Vergou T, Stavropoulos P, Avgerinou G, Rigopoulos D, Katsambas AD.
Infliximab for the treatment of psoriasis in Greece: 4 years of clinical experience at a single centre.
Br J Dermatol. 2010 May;162(5):1117-23.

– Arcese A, Aste N, Bettacchi A, Camplone G, Cantoresi F, Caproni M, D’Amico D, Fabbri P, Filosa G, Galluccio A, Hansel K, Lisi P, Micali G, Musumeci ML, Nicolini M, Parodi A, Patania M, Pezza M, Potenza C, Richetta A, Simonacci M, Trevisan P, Valenti G, Calvieri S.
Treating psoriasis with etanercept in Italian clinical practice: prescribing practices and duration of remission following discontinuation.
Clin Drug Investig. 2010;30(8):507-16.

– Augustin M, Reich K, Blome C, Schäfer I, Laass A, Radtke MA.
Nail psoriasis in Germany: epidemiology and burden of disease.
Br J Dermatol. 2010; 163 (3): 580-5.

– Ayala F, Nino M, Fabbrocini G, Panariello L, Balato N, Foti C, Tosti A, Corazza M, Valsecchi RH, Gola M, Gallo R, Guarneri F, Pigatto PD, Cristaudo A, Schena D, Musumeci ML, Stingeni L, Lisi P.
Quality of life and contact dermatitis: a disease-specific questionnaire.
Dermatitis. 2010 Apr;21(2):84-90.

– Blome C, Simianer S, Purwins S, Laass A, Rustenbach SJ, Schaefer I, Radtke M, Augustin M.
Time needed for treatment is the major predictor of quality of life in psoriasis.
Dermatology. 2010; 221(2):154-9.

– Bronsard V, Paul C, Prey S, Puzenat E, Gourraud PA, Aractingi S, Aubin F, Bagot M, Cribier B, Joly P, Jullien D, Le Maitre M, Richard-Lallemand MA, Ortonne JP.
What are the best outcome measures for assessing quality of life in plaque type psoriasis? A systematic review of the literature.
J Eur Acad Dermatol Venereol. 2010 Apr;24 Suppl 2:17-22.

– Brown BC, Moss TP, McGrouther DA, Bayat A.
Skin scar preconceptions must be challenged: importance of self-perception in skin scarring.
J Plast Reconstr Aesthet Surg. 2010 Jun;63(6):1022-9.

– Choonhakarn C, Busaracome P, Sripanidkulchai B, Sarakarn P.
A prospective, randomized clinical trial comparing topical aloe vera with 0.1% triamcinolone acetonide in mild to moderate plaque psoriasis.
J Eur Acad Dermatol Venereol. 2010 Feb;24(2):168-72.

– Cozzani E, Borrini V, Pennella A, Burlando M, Cardo P, Rebora A, Parodi A.
The quality of life in Italian psoriatic patients treated with biological drugs.
G Ital Dermatol Venereol. 2010 Dec;145(6):709-12.

– Esmann S, Jemec GB.
Is the Dermatology Life Quality Index really time-sensitive?
J Eur Acad Dermatol Venereol. 2010 May;24(5):621-2.

– Esposito M, Giunta A, Mazzotta A, Babino G, Talamonti M, Chimenti MS, Chimenti S.
Continuous treatment of plaque-type psoriasis with etanercept: an observational long-term experience.
Int J Immunopathol Pharmacol. 2010 Apr-Jun;23(2):503-9.

– Grant A, Gonzalez T, Montgomery MO, Cardenas V, Kerdel FA.
Infliximab therapy for patients with moderate to severe hidradenitis suppurativa: a randomized, double-blind, placebo-controlled crossover trial.
J Am Acad Dermatol. 2010 Feb;62(2):205-17.

– Grant P.
Spearmint herbal tea has significant anti-androgen effects in polycystic ovarian syndrome. A randomized controlled trial.
Phytother Res. 2010 Feb;24(2):186-8.

– Hickey S, Bell H.
Quality of life in the vulvar clinic: a pilot study.
J Low Genit Tract Dis. 2010 Jul;14(3):225-9.

– Huang YH, Yang CH, Chen YH, Chen CH, Lee SH.
Reduction in Osmidrosis Using a Suction-Assisted Cartilage Shaver Improves the Quality of Life.
Dermatol Surg. 2010 Oct; 36 (10): 1573-7.

– Ibler KS, Agner T, Hansen JL, Gluud C.
The Hand Eczema Trial (HET): Design of a randomised clinical trial of the effect of classification and individual counselling versus no intervention among health-care workers with hand eczema.
BMC Dermatol. 2010 Aug 31;10:8.

– Ioannides D, Lazaridou E, Apalla Z, Sotiriou E, Gregoriou S, Rigopoulos D.
Acitretin for severe lichen sclerosus of male genitalia: a randomized, placebo controlled study.
J Urol. 2010 Apr;183(4):1395-9.

– Jin-Gang A, Sheng-Xiang X, Sheng-Bin X, Jun-Min W, Song-Mei G, Ying-Ying D, Jung-Hong M, Qing-Qiang X, Xiao-Peng W.
Quality of life of patients with scabies.
J Eur Acad Dermatol Venereol. 2010 Oct; 24 (10): 1187-91.

– Karsai S, Schmitt L, Raulin C.
The pulsed-dye laser as an adjuvant treatment modality in acne vulgaris: a randomized controlled single-blinded trial.
Br J Dermatol. 2010 Aug;163(2):395-401.

– Kavanaugh A, Menter A, Mendelsohn A, Shen YK, Lee S, Gottlieb AB.
Effect of ustekinumab on physical function and health-related quality of life in patients with psoriatic arthritis: a randomized, placebo-controlled, phase II trial.
Curr Med Res Opin. 2010 Oct;26(10):2385-92.

– Kim WO, Kil HK, Yoon KB, Yoo JH.
Treatment of generalized hyperhidrosis with oxybutynin in post-menopausal patients.
Acta Derm Venereol. 2010 May;90(3):291-3.

– Lacouture ME, Mitchell EP, Piperdi B, Pillai MV, Shearer H, Iannotti N, Xu F, Yassine M.
Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-Emptive Skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer.
J Clin Oncol. 2010 Mar 10;28(8):1351-7.

– Lambert J, Bostoen J, Geusens B, Bourgois J, Boone J, De Smedt D, Annemans L.
A novel multidisciplinary educational programme for patients with chronic skin diseases: Ghent pilot project and first results.
Arch Dermatol Res. 2011 Jan; 303 (1): 57-63.

– Langley RG, Feldman SR, Han C, Schenkel B, Szapary P, Hsu MC, Ortonne JP, Gordon KB, Kimball AB.
Ustekinumab significantly improves symptoms of anxiety, depression, and skin-related quality of life in patients with moderate-to-severe psoriasis: Results from a randomized, double-blind, placebo-controlled phase III trial.
J Am Acad Dermatol. 2010 Sep;63(3):457-65.

– Lebwohl M, Papp K, Han C, Schenkel B, Yeilding N, Wang Y, Krueger GG.
Ustekinumab improves health-related quality of life in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial.
Br J Dermatol. 2010 Jan;162(1):137-46.

– Lodén M, Wirén K, Smerud K, Meland N, Hønnås H, Mørk G, Lützow-Holm C, Funk J, Meding B.
Treatment with a barrier-strengthening moisturizer prevents relapse of hand-eczema. An open, randomized, prospective, parallel group study
Acta Derm Venereol. 2010 Nov;90(6):602-6.

– Lyakhovitsky A, Barzilai A, Heyman R, Baum S, Amichai B, Solomon M, Shpiro D, Trau H.
Low-dose methotrexate treatment for moderate-to-severe atopic dermatitis in adults.
J Eur Acad Dermatol Venereol. 2010 Jan;24(1):43-9.

– Magerl M, Pisarevskaja D, Scheufele R, Zuberbier T, Maurer M.
Effects of a pseudoallergen-free diet on chronic spontaneous urticaria: a prospective trial.
Allergy. 2010 Jan;65(1):78-83.

– Marchesoni A, Altomare G, Matucci-Cerinic M, Balato N, Olivieri I, Salvarani C, Lotti T, Scarpa R, Vena GA, Valesini G, Giannetti A.
An Italian shared dermatological and rheumatological proposal for the use of biological agents in psoriatic disease.
J Eur Acad Dermatol Venereol. 2010 May;24(5):578-86.

– Mathias SD, Dreskin SC, Kaplan A, Saini SS, Spector S, Rosén KE.
Development of a daily diary for patients with chronic idiopathic urticaria.
Ann Allergy Asthma Immunol. 2010 Aug;105(2):142-8.

– Matusiak L, Bieniek A, Szepietowski JC.
Psychophysical aspects of hidradenitis suppurativa.
Acta Derm Venereol. 2010 May;90(3):264-8.

– Maziar A, Farsi N, Mandegarfard M, Babakoohi S, Gorouhi F, Dowlati Y, Firooz A.
Unwanted facial hair removal with laser treatment improves quality of life of patients.
J Cosmet Laser Ther. 2010 Feb;12(1):7-9.

– Menter A, Augustin M, Signorovitch J, Yu AP, Wu EQ, Gupta SR, Bao Y, Mulani P.
The effect of adalimumab on reducing depression symptoms in patients with moderate to severe psoriasis: a randomized clinical trial.
J Am Acad Dermatol. 2010 May;62(5):812-8.

– Meyer N, Paul C, Feneron D, Bardoulat I, Thiriet C, Camara C, Sid-Mohand D, Le Pen C, Ortonne JP.
Psoriasis: an epidemiological evaluation of disease burden in 590 patients.
J Eur Acad Dermatol Venereol. 2010 Sep;24(9):1075-82.

– Möller I, Pérez M, Monfort J, Benito P, Cuevas J, Perna C, Doménech G, Herrero M, Montell E, Vergés J.
Effectiveness of chondroitin sulphate in patients with concomitant knee osteoarthritis and psoriasis: a randomized, double-blind, placebo-controlled study.
Osteoarthritis Cartilage. 2010 Jun;18 Suppl 1:S32-40.

– Morsy H, Kamp S, Thrane L, Behrendt N, Saunder B, Zayan H, Elmagid EA, Jemec GB.
Optical coherence tomography imaging of psoriasis vulgaris: correlation with histology and disease severity.
Arch Dermatol Res. 2010 Mar;302(2):105-11.

– Murota H, Kitaba S, Tani M, Wataya-Kaneda M, Azukizawa H, Tanemura A, Umegaki N, Terao M, Kotobuki Y, Katayama I.
Impact of Sedative and Non-Sedative Antihistamines on the Impaired Productivity and Quality of Life in Patients with Pruritic Skin Diseases.
Allergol Int. 2010 Dec; 59(4): 345-54.

– Murray CS, Rees JL.
How robust are the Dermatology Life Quality Index and other self-reported subjective symptom scores when exposed to a range of experimental biases?
Acta Derm Venereol. 2010;90(1):34-8.

– Naldi L, Svensson A, Zenoni D, Diepgen T, Elsner P, Grob JJ, Coenraads PJ, Bouwes Bavinck JN, Maccagni A, Linder D, Williams H; European Dermato-Epidemiology Network.
Comparators, study duration, outcome measures and sponsorship in therapeutic trials of psoriasis: update of the EDEN Psoriasis Survey 2001-2006.
Br J Dermatol. 2010 Feb 1;162(2):384-9.

– Nybaek H, Knudsen DB, Laursen TN, Karlsmark T, Jemec GB.
Quality of life assessment among patients with peristomal skin disease.
Eur J Gastroenterol Hepatol. 2010 Feb;22(2):139-43.

– Navarini AA, Trüeb RM.
[Psoriasis] [Article in German]
Ther Umsch. 2010 Apr;67(4):153-65.

– Oh SH, Bae BK, Kim TG, Kwon YS, Lee JH, Lee KH.
Effective treatment of facial redness caused by atopic dermatitis using intense pulsed light systems.
Dermatol Surg. 2010 Apr;36(4):475-82.

– Oh SH, Bae BG, Park CO, Noh JY, Park IH, Wu WH, Lee KH.
Association of stress with symptoms of atopic dermatitis.
Acta Derm Venereol. 2010 Nov;90(6):582-8.

– Ortonne JP, Baran R, Corvest M, Schmitt C, Voisard JJ, Taieb C.
Development and validation of nail psoriasis quality of life scale (NPQ10).
J Eur Acad Dermatol Venereol. 2010 Jan;24(1):22-7.

– Palota T, Szepietowski JC, Pec J, Arenberger P, Giurcaneanu C, Gyulai R, Miljkovic J, Pärna E, Mikazans I, Grusauskas N, Hodik
A survey of disease severity, quality of life, and treatment patterns of biologically naive patients with psoriasis in central and eastern Europe.
Acta Dermatovenerol Croat. 2010 Sep;18(3):151-61.

– Papp KA, Poulin Y, Bissonnette R, Bourcier M, Toth D, Rosoph L, Poulin-Costello M, Setterfield M, Syrotuik J.
Assessment of the long-term safety and effectiveness of etanercept for the treatment of psoriasis in an adult population.
J Am Acad Dermatol. 2010 Epub Sept 17.

– Paul A, Kranz G, Schindl A, Kranz GS, Auff E, Sycha T.
Diode laser hair removal does not interfere with botulinum toxin A treatment against axillary hyperhidrosis.
Lasers Surg Med. 2010 Mar;42(3):211-4.

– Paul C, Gourraud PA, Bronsard V, Prey S, Puzenat E, Aractingi S, Aubin F, Bagot M, Cribier B, Joly P, Jullien D, Le Maitre M, Richard-Lallemand MA, Ortonne JP.
Evidence-based recommendations to assess psoriasis severity: systematic literature review and expert opinion of a panel of dermatologists.
J Eur Acad Dermatol Venereol. 2010 Apr;24 Suppl 2:2-9.

– Paulden M, Rodgers M, Griffin S, Slack R, Duffy S, Ingram JR, Woolacott N, Sculpher M.
Alitretinoin for the treatment of severe chronic hand eczema.
Health Technol Assess. 2010 May;14 Suppl 1:39-46.

– de Portu S, Del Giglio M, Altomare G, Arcangeli F, Berardesca E, Calzavara-Pinton P, Lotti T, Martini P, Peserico A, Simonacci M, Vena GA, Girolomoni G.
Cost-effectiveness analysis of TNF-alpha blockers for the treatment of chronic plaque psoriasis in the perspective of the Italian health-care system.
Dermatol Ther. 2010 Jan-Feb;23 Suppl 1:S7-13.

– Proto RS, Machado Filho CD, Rehder JR, Paixão MP, Angelucci RI.
Quality of life in leprosy: a comparative analysis between patients in the Amazon region and patients in Santo André in the ABC region of São Paulo, Brazil.
An Bras Dermatol. 2010 Dec;85(6):939-41.

– Reich A, Hrehorów E, Szepietowski JC.
Pruritus is an important factor negatively influencing the well-being of psoriatic patients.
Acta Derm Venereol. 2010 May;90(3):257-63.

– Reich K, Ortonne JP, Kerkmann U, Wang Y, Saurat JH, Papp K, Langley R, Griffiths CE.
Skin and nail responses after 1 year of infliximab therapy in patients with moderate-to-severe psoriasis: a retrospective analysis of the EXPRESS Trial.
Dermatology. 2010;221(2):172-8.

– Rodgers M, Griffin S, Paulden M, Slack R, Duffy S, Ingram JR, Woolacott N, Sculpher M.
Alitretinoin for severe chronic hand eczema: a NICE single technology appraisal.
Pharmacoeconomics. 2010;28(5):351-62.

– Ryan C, Renfro L, Collins P, Kirby B, Rogers S.
Clinical and Genetic Predictors of Response to Narrowband UVB for the Treatment of Chronic Plaque Psoriasis.
Br J Dermatol. 2010 Nov; 163(5): 1056-63.

– Sartorius K, Killasli H, Heilborn J, Jemec GB, Lapins J, Emtestam L.
Interobserver variability of clinical scores in hidradenitis suppurativa is low.
Br J Dermatol. 2010 Jun; 126(6): 1261-8.

– Schäfer I, Hacker J, Rustenbach SJ, Radtke M, Franzke N, Augustin M.
Concordance of the Psoriasis Area and Severity Index (PASI) and patient-reported outcomes in psoriasis treatment.
Eur J Dermatol. 2010 Jan-Feb;20(1):62-7.

– Schmitt J, Schäkel K, Fölster-Holst R, Bauer A, Oertel R, Augustin M, Aberer W, Luger T, Meurer M.
Prednisolone vs. ciclosporin for severe adult eczema. An investigator-initiated double-blind placebo-controlled multicentre trial.
Br J Dermatol. 2010 Mar;162(3):661-8.

– Sikorski C, Ashine M, Zeleke Z, Davey G.
Effectiveness of a simple lymphoedema treatment regimen in podoconiosis management in southern ethiopia: one year follow-up.
PLoS Negl Trop Dis. 2010 Nov 30;4(11):e902.

– Taborda ML, Weber MB, Teixeira KA, Lisboa AP, Welter Ede Q.
[Evaluation of the quality of life and psychological distress of patients with different dermatoses in a dermatology referral center in southern Brazil] [Article in Portuguese]
An Bras Dermatol. 2010 Feb;85(1):52-6.

– Tanioka M, Yamamoto Y, Kato M, Miyachi Y.
Camouflage for patients with vitiligo vulgaris improved their quality of life.
J Cosmet Dermatol. 2010 Mar;9(1):72-5.

– Torii H, Nakagawa H; Japanese Infliximab Study investigators.
Infliximab monotherapy in Japanese patients with moderate-to-severe plaque psoriasis and psoriatic arthritis. A randomized, double-blind, placebo-controlled multicenter trial.
J Dermatol Sci. 2010 Jul;59(1):40-9.

– Van De Nieuwenhof HP, Meeuwis KA, Nieboer TE, Vergeer MC, Massuger LF, De Hullu JA.
The effect of vulvar lichen sclerosus on quality of life and sexual functioning.
J Psychosom Obstet Gynaecol. 2010  Dec;31(4):279-84.

– Vasiuk IuA, Perlamutrov IuN, Shkol’nik MN, Shkol’nik EL.
[Possibilities of atorvastatin in complex management of extensive psoriasis in patients with arterial hypertension]
[Article in Russian]
Kardiologiia. 2010;50(3):37-46.

– Venugopal SS, Intong LR, Cohn HI, Mather-Hillon J, Murrell DF.
Responsiveness of nonHerlitz junctional epidermolysis bullosa to topical gentian violet.
Int J Dermatol. 2010 Nov;49(11):1282-5.

– Wahie S, McColl E, Reynolds NJ, Meggitt SJ.
Measuring disease activity and damage in discoid lupus erythematosus.
Br J Dermatol. 2010 May;162(5):1030-7.

– Wain EM, Darling MI, Pleass RD, Barker JN, Smith CH.
Treatment of severe, recalcitrant, chronic plaque psoriasis with fumaric acid esters: a prospective study.
Br J Dermatol. 2010 Feb 1;162(2):427-34.

– Zuberbier T, Oanta A, Bogacka E, Medina I, Wesel F, Uhl P, Antépara I, Jáuregui I, Valiente R; Bilastine International Working Group.
Comparison of the efficacy and safety of bilastine 20 mg vs levocetirizine 5 mg for the treatment of chronic idiopathic urticaria: a multi-centre, double-blind, randomized, placebo-controlled study.
Allergy. 2010 Apr;65(4):516-28.

2011

– Al-Mutairi N, Eldin ON.
Clinical profile and impact on quality of life: Seven years experience with patients of alopecia areata.
Indian J Dermatol Venereol Leprol. 2011 Jul-Aug;77(4):489-93.

– Al Robaee AA, Alzolibani AA.
Narrowband ultraviolet B phototherapy improves the quality of life in patients with psoriasis.
Saudi Med J. 2011 Jun;32(6):603-6.

– Amano M, Grant A, Kerdel FA.
A prospective open-label clinical trial of adalimumab for the treatment of hidradenitis suppurativa.
Int J Dermatol. 2010 Aug;49(8):950-5.

– Babayeva L, Akarsu S, Fetil E, Güneş AT.
Comparison of tretinoin 0.05% cream and 3% alcohol-based salicylic acid preparation in the treatment of acne vulgaris.
J Eur Acad Dermatol Venereol. 2011 Mar;25(3):328-33.

– Barker J, Hoffmann M, Wozel G, Ortonne JP, Zheng H, van Hoogstraten H, Reich K.
Efficacy and safety of infliximab vs. methotrexate in patients with moderate-to-severe plaque psoriasis: results of an open-label, active-controlled, randomized trial (RESTORE1).
Br J Dermatol. 2011 Nov;165(5):1109-17.

– Bell HK, Duncan AL.
The use of the Dermatology Life Quality Index in patients with malignant carcinoid syndrome.
Br J Dermatol. 2011 Sep 14. doi: 10.1111/j.1365-2133.2011.10617.x. [Epub ahead of print]

– Berg M, Lindberg M.
Possible gender differences in the quality of life and choice of therapy in acne.
J Eur Acad Dermatol Venereol. 2011 Aug;25(8):969-72.

– Bodemer C, Bourrat E, Mazereeuw-Hautier J, Boralevi F, Barbarot S, Bessis D, Blanchet-Bardon C, Bourdon-Lanoy E, Stalder JF, Ribet V, Guerrero D, Sibaud V.
Short- and medium-term efficacy of specific hydrotherapy in inherited ichthyosis.
Br J Dermatol. 2011 Nov;165(5):1087-94.

– Brzoza Z, Badura-Brzoza K, Młynek A, Magerl M, Baiardini I, Canonica GW, Weller K, Kocatürk E, Kalogeromitros D, Zalewska-Janowska A, Zuberbier T, Maurer M.
Adaptation and initial results of the Polish version of the GA(2)LEN chronic urticaria quality of life questionnaire (CU-Q(2)oL).
J Dermatol Sci. 2011 Apr;62(1):36-41.

– Budel AR, Raymundo AR, Costa CF, Gerhardt C, Pedri LE.
Profile of patients affected by Hansen’s disease seen at the Outpatient Clinic of Dermatology at Hospital Evangélico de Curitiba.
An Bras Dermatol. 2011 Oct;86(5):942-946.

– Campanati A, Sandroni L, Gesuita R, Giuliano A, Giuliodori K, Marconi B, Ganzetti G, Offidani A.
Treatment of focal idiopathic hyperhidrosis with Botulinum Toxin Type A: clinical predictive factors of relapse-free survival.
J Eur Acad Dermatol Venereol. 2011 Aug; 25(8): 917-21.

– Chambers CJ, Parsi KK, Schupp C, Armstrong AW.
Patient-centered online management of psoriasis: A randomized controlled equivalency trial.
J Am Acad Dermatol. 2011 Sep 2. [Epub ahead of print]

– Chan SA, Hussain F, Lawson LG, Ormerod AD.
Factors affecting adherence to treatment of psoriasis: comparing biologic therapy to other modalities.
J Dermatolog Treat. 2011 Sep 7. [Epub ahead of print]

– Chernyshov PV, Bylaĭte M.
[Comparative study of quality of life in patients with psoriasis from Lithuania and Ukraine].
[Article in Ukrainian]
Lik Sprava. 2010 Oct-Dec;(7-8):107-11.

– Chew AL, Bashir SJ, Johnston A, Barker JN, Smith CH.
The value of monitoring ciclosporin concentration 2 hours post-dose (C2) in dermatology: a prospective cohort study.
J Dermatolog Treat. 2011 Apr;22(2):79-85.

– Chularojanamontri L, Sethabutra P, Kulthanan K, Manapajon A.
Dermatology life quality index in Thai patients with systemic sclerosis: a cross-sectional study.
Indian J Dermatol Venereol Leprol. 2011 Nov-Dec;77(6):683-7.

– Coimbra S, Oliveira H, Reis F, Belo L, Carvalho A, Figueiredo A, Teixeira F, Castro E, Rocha-Pereira P, Santos-Silva A.
Health-related quality of life in Portuguese psoriatic patients: Relation with Psoriasis Area and Severity Index and different types of classical psoriatic treatment.
J Dermatol. 2011 Aug; 38 (8): 816-9.

– Cozzani E, Borrini V, Pennella A, Burlando M, Cardo P, Rebora A, Parodi A.
The quality of life in Italian psoriatic patients treated with biological drugs.
G Ital Dermatol Venereol. 2010 Dec;145(6):709-12.

– Dastgheib L, Jowkar F, Abdollahee A, Namazi MR.
Mesalazine as a new therapeutic option for chronic idiopathic urticaria.
J Dermatolog Treat. 2011 Jul 19. [Epub ahead of print]

– Daudén E, Sánchez-Perez J, Prieto M, Roset M.
[Validation of the Spanish Version of the Itch Severity Scale: the PSEDA study].
[Article in Spanish]
Actas Dermosifiliogr. 2011 Sep;102(7):527-36.

– Dias GA, Pires GV, Valle SO, França AT, Papi JA, Dortas SD Jr, Levy SA, Baiardini I, Canonica GW.
Cross-cultural adaptation of the Brazilian-Portuguese version of the chronic urticaria quality-of-life questionnaire – CU-Q2oL.
Allergy. 2011 Nov;66(11):1487-93.

– Dodiuk-Gad R, Cohen-Barak E, Ziv M, Shani-Adir A, Amichai B, Zlotogorski A, Shalev S, Rozenman D.
Health-related quality of life among Darier’s disease patients.
J Eur Acad Dermatol Venereol. 2011 Nov 28. doi: 10.1111/j.1468-3083.2011.04355.x. [Epub ahead of print]

– Drago L, Iemoli E, Rodighiero V, Nicola L, De Vecchi E, Piconi S.
Effects of Lactobacillus salivarius LS01 (DSM 22775) treatment on adult atopic dermatitis: a randomized placebo-controlled study.
Int J Immunopathol Pharmacol. 2011 Oct-Dec;24(4):1037-48.

– Elewski BE, Cantrell WC.
An open-label study of the safety and efficacy of sertaconazole nitrate in the treatment of seborrheic dermatitis.
J Drugs Dermatol. 2011 Aug;10(8):895-9.

– Ermertcan AT, Gencoglan G, Temeltas G, Horasan GD, Deveci A, Ozturk F.
Sexual dysfunction in female patients with neurodermatitis.
J Androl. 2011 Mar-Apr;32(2):165-9.

– Ersser SJ, Cowdell FC, Nicholls PG, Latter SM, Healy E.
A pilot randomized controlled trial to examine the feasibility and efficacy of an educational nursing intervention to improve self-management practices in patients with mild-moderate psoriasis.
J Eur Acad Dermatol Venereol. 2011 Jun 28. doi: 10.1111/j.1468-3083.2011.04158.x. [Epub ahead of print]

– Ghodsi SZ, Chams-Davatchi C, Daneshpazhooh M, Valikhani M, Esmaili N.
Quality of life and psychological status of patients with pemphigus vulgaris using Dermatology Life Quality Index and General Health Questionnaires.
J Dermatol. 2011 Oct 4. doi: 10.1111/j.1346-8138.2011.01382.x. [Epub ahead of print]

– Gniadecki R, Robertson D, Molta CT, Freundlich B, Pedersen R, Li W, Boggs R, Zbrozek AS.
Self-reported health outcomes in patients with psoriasis and psoriatic arthritis randomized to two etanercept regimens.
J Eur Acad Dermatol Venereol. 2011 Oct 31. doi: 10.1111/j.1468-3083.2011.04308.x. [Epub ahead of print]

– Goreshi R, Chock M, Foering K, Feng R, Okawa J, Rose M, Fiorentino D, Werth V.
Quality of life in dermatomyositis.
J Am Acad Dermatol. 2011 Dec;65(6):1107-16.

– Goulding JM, Price CL, Defty CL, Hulangamuwa CS, Bader E, Ahmed I.
Erectile dysfunction in patients with psoriasis: increased prevalence, an unmet need, and a chance to intervene.
Br J Dermatol. 2011 Jan;164(1):103-9.

– Guenther L, Han C, Szapary P, Schenkel B, Poulin Y, Bourcier M, Ortonne JP, Sofen HL.
Impact of ustekinumab on health-related quality of life and sexual difficulties associated with psoriasis: results from two phase III clinical trials.
J Eur Acad Dermatol Venereol. 2011 Jul;25(7):851-7.

– Gulliver WP, Jemec GB, Baker KA.
Experience with ustekinumab for the treatment of moderate to severe Hidradenitis suppurativa.
J Eur Acad Dermatol Venereol. 2011 May 24. doi: 10.1111/j.1468-3083.2011.04123.x. [Epub ahead of print]

– He Z, Lu C, Basra MK, Ou A, Yan Y, Li L.
Psychometric properties of the Chinese version of dermatology life quality index (DLQI) in 851 Chinese patients with psoriasis.
J Eur Acad Dermatol Venereol. 2011 Dec 7. doi: 10.1111/j.1468-3083.2011.04371.x. [Epub ahead of print]

– He J, Wang T, Dong J.
Excision of apocrine glands and axillary superficial fascia as a single entity for the treatment of axillary bromhidrosis.
J Eur Acad Dermatol Venereol. 2011 Jun 21. doi: 10.1111/j.1468-3083.2011.04149.x. [Epub ahead of print]

– Hon KL, Chan IH, Chow CM, Wang SS, Lam CW, Ng PC, Leung TF.
Specific IgE of common foods in Chinese children with eczema.
Pediatr Allergy Immunol. 2011 Feb;22(1 Pt 1):50-3.

– Igarashi A, Kato T, Kato M, Song M, Nakagawa H; THE JAPANESE USTEKINUMAB STUDY GROUP.
Efficacy and safety of ustekinumab in Japanese patients with moderate-to-severe plaque-type psoriasis: Long-term results from a phase 2/3 clinical trial.
J Dermatol. 2011 Sep 29. doi: 10.1111/j.1346-8138.2011.01347.x. [Epub ahead of print]

– Kaiser CA, Cozzio A, Hofbauer GF, Kamarashev J, French LE, Navarini AA.
Disfiguring annular sarcoidosis improved by adalimumab.
Case Rep Dermatol. 2011 May;3(2):103-6.

– Kamalpour L, Gammon B, Chen KH, Veledar E, Pavlis M, Rice ZP, Chen SC.
Resource utilization and quality of life associated with congenital ichthyoses.
Pediatr Dermatol. 2011 Sep-Oct;28(5):512-8.

– Kavanaugh A, Menter A, Mendelsohn A, Shen YK, Lee S, Gottlieb AB.
Effect of ustekinumab on physical function and health-related quality of life in patients with psoriatic arthritis: a randomized, placebo-controlled, phase II trial.
Curr Med Res Opin. 2010 Oct;26(10):2385-92.

– Kim KH, Kono T.
Overview of efficacy and safety of tacrolimus ointment in patients with atopic dermatitis in Asia and other areas.
Int J Dermatol. 2011 Sep;50(9):1153-61.

– Kimball AB, Bensimon AG, Guerin A, Yu AP, Wu EQ, Okun MM, Bao Y, Gupta SR, Mulani PM.
Efficacy and safety of adalimumab among patients with moderate to severe psoriasis with co-morbidities: Subanalysis of results from a randomized, double-blind, placebo-controlled, phase III trial.
Am J Clin Dermatol. 2011 Feb 1;12(1):51-62.

– Kimball AB, Yu AP, Signorovitch J, Xie J, Tsaneva M, Gupta SR, Bao Y, Mulani PM.
The effects of adalimumab treatment and psoriasis severity on self-reported work productivity and activity impairment for patients with moderate to severe psoriasis.
J Am Acad Dermatol. 2011 May 24. [Epub ahead of print]

– Kluger N, Letois F, Picot MC, Guillot B, Bessis D.
How much disability is caused by fibrofolliculomas during Birt-Hogg-Dubé Syndrome?
J Eur Acad Dermatol Venereol. 2011 Aug;25(8):940-4.

– Kocatürk E, Aktaş S, Türkoğlu Z, Kavala M, Zindanci I, Koc M, Can B, Südoğan S.
Autologous whole blood and autologous serum injections are equally effective as placebo injections in reducing disease activity in patients with chronic spontaneous urticaria: a placebo controlled, randomized, single-blind study.
J Dermatolog Treat. 2011 Jul 31. [Epub ahead of print]

– Kocatürk E, Kavala M, Kural E, Sarıgul S, Zındancı I.
Autologous serum skin test vs autologous plasma skin test in patients with chronic urticaria: evaluation of reproducibility, sensitivity and specificity and relationship with disease activity, quality of life and anti-thyroid antibodies.
Eur J Dermatol. 2011 May-Jun;21(3):339-43.

– Kocatürk E, Weller K, Martus P, Aktas S, Kavala M, Sarigul S, Baiardini I, Canonica GW, Brzoza Z, Kalogeromitros D, Maurer M.
Turkish Version of the Chronic Urticaria Quality of Life Questionnaire: Cultural Adaptation, Assessment of Reliability and Validity.
Acta Derm Venereol. 2011 Sep 15. doi: 10.2340/00015555-1199. [Epub ahead of print]

– Krenzer S, Radtke M, Schmitt-Rau K, Augustin M.
Characterization of patient-reported outcomes in moderate to severe psoriasis.
Dermatology. 2011;223(1):80-6.

– Krüger C, Smythe JW, Spencer JD, Hasse S, Panske A, Chiuchiarelli G, Schallreuter KU.
Significant immediate and long-term improvement in quality of life and disease coping in patients with vitiligo after group climatotherapy at the Dead Sea.
Acta Derm Venereol. 2011 Mar;91(2):152-9.

– Kunynetz R, Carey W, Thomas R, Toth D, Trafford T, Vender R.
Quality of life in plaque psoriasis patients treated with voclosporin: a Canadian phase III, randomized, multicenter, double-blind, placebo-controlled study.
Eur J Dermatol. 2011 Jan-Feb;21(1):89-94.

– Kurek A, Peters EM, Chanwangpong A, Sabat R, Sterry W, Schneider-Burrus S.
Profound disturbances of sexual health in patients with acne inversa.
J Am Acad Dermatol. 2011 Dec 17. [Epub ahead of print]

– Kurzeja M, Rudnicka L, Olszewska M.
New interleukin-23 pathway inhibitors in dermatology: ustekinumab, briakinumab, and secukinumab.
Am J Clin Dermatol. 2011 Apr 1;12(2):113-25.

– Lambert J, Bostoen J, Geusens B, Bourgois J, Boone J, De Smedt D, Annemans L.
A novel multidisciplinary educational programme for patients with chronic skin diseases: Ghent pilot project and first results.
Arch Dermatol Res. 2011 Jan;303(1):57-63.

– Langenbruch AK, Beket E, Augustin M.
Quality of Health Care of Rosacea in Germany from the Patient’s Perspective: Results of the National Health Care Study RosaReal 2009.
Dermatology. 2011;223(2):124-30.

– Langley RG, Paller AS, Hebert AA, Creamer K, Weng HH, Jahreis A, Globe D, Patel V, Orlow SJ.
Patient-reported outcomes in pediatric patients with psoriasis undergoing etanercept treatment: 12-week results from a phase III randomized controlled trial.
J Am Acad Dermatol. 2011 Jan;64(1):64-70.

– Lau MY, Burgess JA, Nixon R, Dharmage SC, Matheson MC.
A review of the impact of occupational contact dermatitis on quality of life.
J Allergy (Cairo). 2011;2011:964509. Epub 2011 Mar 16.

– Lau MY, Matheson MC, Burgess JA, Dharmage SC, Nixon R.
Disease severity and quality of life in a follow-up study of patients with occupational contact dermatitis.
Contact Dermatitis. 2011 Sep;65(3):138-45.

– Leeyaphan C, Wanitphakdeedecha R, Manuskiatti W, Kulthanan K.
Measuring Melasma Patients’ Quality of Life using Willingness to Pay and Time Trade-off Methods in Thai Population.
BMC Dermatol. 2011 Dec 19;11(1):16. [Epub ahead of print]

– Lin TY, See LC, Shen YM, Liang CY, Chang HN, Lin YK.
Quality of life in patients with psoriasis in northern Taiwan.
Chang Gung Med J. 2011 Mar-Apr;34(2):186-96.

– Liu JB, Yao MZ, Si AL, Xiong LK, Zhou H.
Life quality of Chinese patients with chronic urticaria as assessed by the dermatology life quality index.
J Eur Acad Dermatol Venereol. 2011 Sep 29. doi: 10.1111/j.1468-3083.2011.04277.x. [Epub ahead of print]

– Ljosaa T, Mork C, Stubhaug A, Moum T, Wahl A.
Skin pain and skin discomfort is associated with quality of life in patients with psoriasis.
J Eur Acad Dermatol Venereol. 2011 Mar 8. doi: 10.1111/j.1468-3083.2011.04000.x. [Epub ahead of print]

– Lodén M, Wirén K, Smerud KT, Meland N, Hønnås H, Mørk G, Lützow-Holm C, Funk J, Meding B.
The effect of a corticosteroid cream and a barrier-strengthening moisturizer in hand eczema. A double-blind, randomized, prospective, parallel group clinical trial.
J Eur Acad Dermatol Venereol. 2011 May 24. doi: 10.1111/j.1468-3083.2011.04128.x. [Epub ahead of print]

– Mackenzie H, Thavaneswaran A, Chandran V, Gladman DD.
Patient-reported Outcome in Psoriatic Arthritis: A Comparison of Web-based Versus Paper-completed Questionnaires.
J Rheumatol. 2011 Dec;38(12):2619-24.

– Madarasingha NP, de Silva P, Satgurunathan K.
Validation study of Sinhala version of the dermatology life quality index (DLQI).
Ceylon Med J. 2011 Mar;56(1):18-22.

– Maksimović N, Janković S, Marinković J, Sekulović LK, Zivković Z, Spirić VT.
Health-related quality of life in patients with atopic dermatitis.
J Dermatol. 2011 Nov 2. doi: 10.1111/j.1346-8138.2011.01295.x. [Epub ahead of print]

– Meeuwis KA, de Hullu JA, van de Nieuwenhof HP, Evers AW, Massuger LF, van de Kerkhof PC, van Rossum MM.
Quality of life and sexual health in patients with genital psoriasis.
Br J Dermatol. 2011 Jun;164(6):1247-55.

– Miller I, Lynggaard CD, Lophaven S, Zachariae C, Dufour DN, Jemec GB.
A double-blind placebo-controlled randomized trial of adalimumab in the treatment of hidradenitis suppurativa.
Br J Dermatol. 2011 Aug;165(2):391-8.

– Mrowietz U, Kragballe K, Nast A, Reich K.
Strategies for improving the quality of care in psoriasis with the use of treatment goals–a report on an implementation meeting.
J Eur Acad Dermatol Venereol. 2011 May;25 Suppl 3:1-13.

– Mrowietz U, Kragballe K, Reich K, Spuls P, Griffiths CE, Nast A, Franke J, Antoniou C, Arenberger P, Balieva F, Bylaite M, Correia O, Daudén E, Gisondi P, Iversen L, Kemény L, Lahfa M, Nijsten T, Rantanen T, Reich A, Rosenbach T, Segaert S, Smith C, Talme T, Volc-Platzer B, Yawalkar N.
Definition of treatment goals for moderate to severe psoriasis: a European consensus.
Arch Dermatol Res. 2011 Jan;303(1):1-10.

– Norlin JM, Steen Carlsson K, Persson U, Schmitt-Egenolf M.
Analysis of Three Outcome Measures in Moderate to Severe Psoriasis -A Registry Based Study of 2.450 Patients.
Br J Dermatol. 2011 Dec 19. doi: 10.1111/j.1365-2133.2011.10778.x. [Epub ahead of print]

– Novak N, Thaci D, Hoffmann M, Fölster-Holst R, Biedermann T, Homey B, Schaekel K, Stefan JA, Werfel T, Bieber T, Sager A, Zuberbier T.
Subcutaneous immunotherapy with a depigmented polymerized birch pollen extract–a new therapeutic option for patients with atopic dermatitis.
Int Arch Allergy Immunol. 2011;155(3):252-6.

– Panahi Y, Davoudi SM, Madanchi N, Abolhasani E.
Recombinant human interferon gamma (Gamma Immunex) in treatment of atopic dermatitis.
Clin Exp Med. 2011 Nov 19. [Epub ahead of print]

– Panahi Y, Sahebkar A, Amiri M, Davoudi SM, Beiraghdar F, Hoseininejad SL, Kolivand M.
Improvement of sulphur mustard-induced chronic pruritus, quality of life and antioxidant status by curcumin: results of a randomised, double-blind, placebo-controlled trial.
Br J Nutr. 2011 Nov 18:1-8. [Epub ahead of print]

– Parsi K, Chambers CJ, Armstrong AW.
Cost-effectiveness analysis of a patient-centered care model for management of psoriasis.
J Am Acad Dermatol. 2011 Aug 9. [Epub ahead of print]

– Panahi Y, Davoudi SM, Beiraghdar F, Amiri M.
Doxepin cream vs betamethasone cream for treatment of chronic skin lesions due to sulfur mustard.
Skinmed. 2011 May-Jun;9(3):152-8.

– Papp KA, Signorovitch J, Ramakrishnan K, Yu AP, Gupta SR, Bao Y, Mulani PM.
Effects of adalimumab versus placebo on risk of symptom worsening in psoriasis and subsequent impacts on health-related quality-of-life: analysis of pooled data from two randomized, double-blind, placebo-controlled, multicentre clinical trials.
Clin Drug Investig. 2011;31(1):51-60.

– Pelletier F, Parratte B, Penz S, Moreno JP, Aubin F, Humbert P.
Efficacy of high doses of botulinum toxin A for treating provoked vestibulodynia.
Br J Dermatol. 2011 Mar;164(3):617-22.

– Pflugfelder A, Welter AK, Leiter U, Weide B, Held L, Eigentler T, Dirschka T, Stockfleth E, Nashan D, Garbe C.
Open label randomized study comparing 3 months vs. 6 months treatment of actinic keratoses with 3% diclofenac in 2.5% hyaluronic acid gel: a trial of the German Dermatologic Cooperative Oncology Group.
J Eur Acad Dermatol Venereol. 2011 Mar 18. doi: 10.1111/j.1468-3083.2011.04005.x. [Epub ahead of print]

– Proto RS, Machado Filho CD, Rehder JR, Paixão MP, Angelucci RI.
Quality of life in leprosy: a comparative analysis between patients in the Amazon region and patients in Santo André in the ABC region of São Paulo, Brazil.
An Bras Dermatol. 2010 Dec;85(6):939-41.

– Rehal B, Armstrong AW.
Health outcome measures in atopic dermatitis: a systematic review of trends in disease severity and quality-of-life instruments 1985-2010.
PLoS One. 2011 Apr 13;6(4):e17520.

– Rosen CF, Mussani F, Chandran V, Eder L, Thavaneswaran A, Gladman DD.
Patients with psoriatic arthritis have worse quality of life than those with psoriasis alone.
Rheumatology (Oxford). 2011 Dec 6. [Epub ahead of print]

– Safikhani S, Sundaram M, Bao Y, Mulani P, Revicki DA.
Qualitative assessment of the content validity of the Dermatology Life Quality Index in patients with moderate to severe psoriasis.
J Dermatolog Treat. 2011 Nov 10. [Epub ahead of print]

– Sahni K, Parsad D, Kanwar AJ, Mehta SD.
Autologous noncultured melanocyte transplantation for stable vitiligo: can suspending autologous melanocytes in the patients’ own serum improve repigmentation and patient satisfaction?
Dermatol Surg. 2011 Feb;37(2):176-82.

– Sato R, Milligan G, Molta C, Singh A.
Health-related quality of life and healthcare resource use in European patients with plaque psoriasis: an association independent of observed disease severity.
Clin Exp Dermatol. 2011 Jan;36(1):24-8.

– Schaarschmidt ML, Schmieder A, Umar N, Terris D, Goebeler M, Goerdt S, Peitsch WK.
Patient preferences for psoriasis treatments: process characteristics can outweigh outcome attributes.
Arch Dermatol. 2011 Nov;147(11):1285-94.

– Schuster A, Lesshafft H, Talhari S, Guedes de Oliveira S, Ignatius R, Feldmeier H.
Life quality impairment caused by hookworm-related cutaneous larva migrans in resource-poor communities in manaus, Brazil.
PLoS Negl Trop Dis. 2011 Nov;5(11):e1355.

– See A, Teo B, Kwan R, Lim R, Lee J, Tang MB, Verkooijen HM.
Use of complementary and alternative medicine among dermatology outpatients in Singapore.
Australas J Dermatol. 2011 Feb;52(1):7-13.

– Shah SK, Arthur A, Yang YC, Stevens S, Alexis AF.
A retrospective study to investigate racial and ethnic variations in the treatment of psoriasis with etanercept.
J Drugs Dermatol. 2011 Aug;10(8):866-72.

– Sibaud V, Dalenc F, Chevreau C, Roché H, Delord JP, Mourey L, Lacaze JL, Rahhali N, Taïeb C.
HFS-14, a specific quality of life scale developed for patients suffering from hand-foot syndrome.
Oncologist. 2011;16(10):1469-78.

– Silvares MR, Fortes MR, Miot HA.
Quality of life in chronic urticaria: a survey at a public university outpatient clinic, Botucatu (Brazil).
Rev Assoc Med Bras. 2011 Oct;57(5):577-82.[Article in English, Portuguese]

– Skroza N, Bernardini N, La Torre G, La Viola G, Potenza C.
Correlation between Dermatology Life Quality Index and Minor test and differences in their levels over time in patients with axillary hyperhidrosis treated with botulinum toxin type A.
Acta Dermatovenerol Croat. 2011 Mar;19(1):16-20.

– Skudlik C, Weisshaar E, Scheidt R, Elsner P, Wulfhorst B, Schönfeld M, Malte John S, Ludwig Diepgen T; for the ROQ Study Group.
First results from the multicentre study Rehabilitation of Occupational Skin Diseases – Optimization and Quality Assurance of Inpatient Management (ROQ).
Contact Dermatitis. 2011 Nov 9. doi: 10.1111/j.1600-0536.2011.01991.x. [Epub ahead of print]

– Sola-Ortigosa J, Sánchez-Regaña M, Umbert-Millet P.
Efficacy of adalimumab in the treatment of psoriasis: A retrospective study of 15 patients in daily practice.
J Dermatolog Treat. 2011 Jul 25. [Epub ahead of print]

– Spandonaro F, Altomare G, Berardesca E, Calzavara-Pinton P, Chimenti S, Girolomoni G, Peserico A, Guerra AP, Vena GA, Polistena B, Ayala F.
Health-related quality of life in psoriasis: an analysis of Psocare project patients.
G Ital Dermatol Venereol. 2011 Jun;146(3):169-77.

– Staidle JP, Dabade TS, Feldman SR.
A pharmacoeconomic analysis of severe psoriasis therapy: a review of treatment choices and cost efficiency.
Expert Opin Pharmacother. 2011 Sep;12(13):2041-54.

– Steinbauer J, Koller M, Kohl E, Karrer S, Landthaler M, Szeimies RM.
Quality of life in health care of non-melanoma skin cancer – results of a pilot study.
J Dtsch Dermatol Ges. 2011 Feb;9(2):129-35.

– Szepietowski JC, Balaskas E, Taube KM, Taberly A, Dupuy P; Uraemic Xerosis Working Group.
Quality of life in patients with uraemic xerosis and pruritus.
Acta Derm Venereol. 2011 May;91(3):313-7.

– Tadros A, Vergou T, Stratigos AJ, Tzavara C, Hletsos M, Katsambas A, Antoniou C.
Psoriasis: is it the tip of the iceberg for the quality of life of patients and their families?
J Eur Acad Dermatol Venereol. 2011 Nov;25(11):1282-7.

– Taieb C, Sibaud V, Merial-Kieny C.
Impact of Avène hydrotherapy on the quality of life of atopic and psoriatic patients.
J Eur Acad Dermatol Venereol. 2011 Feb;25 Suppl 1:24-9.

– Tan JY, Li S, Yang K, Ma B, Chen W, Zha C, Zhang J.
Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: a meta-analysis.
J Dermatolog Treat. 2011 Dec;22(6):323-36.

– Tejada Cdos S, Mendoza-Sassi RA, Almeida HL Jr, Figueiredo PN, Tejada VF.
Impact on the quality of life of dermatological patients in southern Brazil.
An Bras Dermatol. 2011 Dec;86(6):1113-21.

– Töndury B, Muehleisen B, Ballmer-Weber BK, Hofbauer G, Schmid-Grendelmeier P, French L, Büchi S.
The Pictorial Representation of Illness and Self Measure (PRISM) instrument reveals a high burden of suffering in patients with chronic urticaria.
J Investig Allergol Clin Immunol. 2011;21(2):93-100.

– Torii H, Sato N, Yoshinari T, Nakagawa H; The Japanese Infliximab Study Investigators.
Dramatic impact of a Psoriasis Area and Severity Index 90 response on the quality of life in patients with psoriasis: An analysis of Japanese clinical trials of infliximab.
J Dermatol. 2011 Dec 29. doi: 10.1111/j.1346-8138.2011.01459.x. [Epub ahead of print]

– Tsai TF, Ho JC, Song M, Szapary P, Guzzo C, Shen YK, Li S, Kim KJ, Kim TY, Choi JH, Youn JI; PEARL Investigators.
Efficacy and safety of ustekinumab for the treatment of moderate-to-severe psoriasis: a phase III, randomized, placebo-controlled trial in Taiwanese and Korean patients (PEARL).
J Dermatol Sci. 2011 Sep;63(3):154-63.

– Twiss J, Meads DM, Preston EP, Crawford SR, McKenna SP.
Can We Rely on the Dermatology Life Quality Index as a Measure of the Impact of Psoriasis or Atopic Dermatitis?
J Invest Dermatol. 2011 Sep 1. doi: 10.1038/jid.2011.238. [Epub ahead of print]

– Valenzuela F, Silva P, Valdés MP, Papp K.
Epidemiology and quality of life of patients with psoriasis in Chile.
Actas Dermosifiliogr. 2011 Dec;102(10):810-6.

– Vender R.
An open-label, prospective cohort pilot study to evaluate the efficacy and safety of etanercept in the treatment of moderate to severe plaque psoriasis in patients who have not had an adequate response to adalimumab.
J Drugs Dermatol. 2011 Apr;10(4):396-402.

– Wang KY, Wang KH, Zhang ZP.
Health-related quality of life and marital quality of vitiligo patients in China.
J Eur Acad Dermatol Venereol. 2011 Apr; 25(4): 429-35.

– Weisshaar E, Ständer S, Gieler U, Matterne U, Darsow U.
[Development of a German language questionnaire for assessing chronic pruritus (AGP-questionnaire) : Background and first results.]
[Article in German]
Hautarzt. 2011 Oct 12. [Epub ahead of print]

– Yamazaki M, Miyakura T, Uchiyama M, Hobo A, Irisawa R, Tsuboi R.
Oral finasteride improved the quality of life of androgenetic alopecia patients.
J Dermatol. 2011 Aug;38(8):773-7.

– Yüksek J, Sezer E, Aksu M, Erkokmaz U.
Transcutaneous electrical nerve stimulation for reduction of pruritus in macular amyloidosis and lichen simplex.
J Dermatol. 2011 Jun;38(6):546-52.

– Zhou ZL, Zhang JP, Wang XM, Shao Q, Hu JY, Han QD.
[Compliance of the patients and related influential factors on the topical antifungal treatment of onychomycosis].
[Article in Chinese]
Zhonghua Liu Xing Bing Xue Za Zhi. 2011 Jul;32(7):720-3.

2012

– Ahern T, Tobin AM, Corrigan M, Hogan A, Sweeney C, Kirby B, O’Shea D.
Glucagon-like peptide-1 analogue therapy for psoriasis patients with obesity and type 2 diabetes: a prospective cohort study.
J Eur Acad Dermatol Venereol. 2012 Jun 13. doi: 10.1111/j.1468-3083.2012.04609.x. [Epub ahead of print]

– Akarsu S, Fetil E, Yücel F, Gül E, Güneş AT.
Efficacy of the addition of salicylic acid to clindamycin and benzoyl peroxide combination for acne vulgaris.
J Dermatol. 2012 May;39(5):433-8.

– Anemüller W, Recke A, Altgassen C, Kelling K.
Developing an interdisciplinary consultation service for vulvar disorders.
J Dtsch Dermatol Ges. 2012 May;10(5):350-7.

– Au SC, Goldminz AM, Kim N, Dumont N, Michelon M, Volf E, Hession M, Lizzul PF, Andrews ID, Kerensky T, Wang A, Yaniv S, Gottlieb AB.
Investigator-initiated, open-label trial of ustekinumab for the treatment of moderate-to-severe palmoplantar psoriasis.
J Dermatolog Treat. 2013 Jun;24(3):179-87.

– Augustin M, Blome C, Zschocke I, Schäfer I, Koenig S, Rustenbach SJ, Herberger K.
Benefit evaluation in the therapy of chronic wounds from the patients’ perspective–development and validation of a new method.
Wound Repair Regen. 2012 Jan-Feb;20(1):8-14.

– Baker EL, Coleman CI, Reinhart KM, Phung OJ, Kugelman L, Chen W, White CM, Mamolo CM, Cappelleri JC, Baker WL.
Effect of Biologic Agents on Non-PASI Outcomes in Moderate-to-Severe Plaque Psoriasis: Systematic Review and Meta-Analyses.
Dermatol Ther (Heidelb). 2012 Dec;2(1):9.

– Basra MK, Chowdhury MM, Smith EV, Freemantle N, Piguet V.
A review of the use of the dermatology life quality index as a criterion in clinical guidelines and health technology assessments in psoriasis and chronic hand eczema.
Dermatol Clin. 2012 Apr;30(2):237-44.

– Basra MK, Hussain S.
Application of the dermatology life quality index in clinical trials of biologics for psoriasis.
Chin J Integr Med. 2012 Mar;18(3):179-85.

– Bell HK, Duncan AL.
The use of the Dermatology Life Quality Index in patients with malignant carcinoid syndrome.
Br J Dermatol. 2012 Feb;166(2):460.

– Boehm D, Schmid-Ott G, Finkeldey F, John SM, Dwinger C, Werfel T, Diepgen TL, Breuer K.
Anxiety, depression and impaired health-related quality of life in patients with occupational hand eczema.
Contact Dermatitis. 2012 Oct;67(4):184-92.

– Böhm M, Ehrchen J, Luger TA.
Beneficial effects of the melanocortin analogue Nle(4) -d-Phe(7) -α-MSH in acne vulgaris.
J Eur Acad Dermatol Venereol. 2012 Jul 27. doi: 10.1111/j.1468-3083.2012.04658.x. [Epub ahead of print]

– Bonifati C, Elia F, Francesconi F, Ceralli F, Izzi S, Solivetti FM, De Mutiis C.
The diagnosis of early psoriatic arthritis in an outpatient dermatological centre for psoriasis.
J Eur Acad Dermatol Venereol. 2012 May;26(5):627-33.

– Bostoen J, Bracke S, De Keyser S, Lambert J.
An educational programme for patients with psoriasis and atopic dermatitis: a prospective randomized controlled trial.
Br J Dermatol. 2012 Nov;167(5):1025-31.

– Bottene IM, Reis VM.
Quality of life of patients with paucibacillary leprosy.
An Bras Dermatol. 2012 May-Jun;87(3):408-11.

– Budania A, Parsad D, Kanwar AJ, Dogra S.
Comparison between autologous noncultured epidermal cell suspension and suction blister epidermal grafting in stable vitiligo: a randomized study.
Br J Dermatol. 2012 Dec;167(6):1295-301.

– Bushnell DM, Martin ML, McCarrier K, Gordon K, Chiou CF, Huang X, Ortmeier B, Kricorian G.
Validation of the Psoriasis Symptom Inventory (PSI), a patient-reported outcome measure to assess psoriasis symptom severity.
J Dermatolog Treat. 2012 Dec 8. [Epub ahead of print]

– Chambers CJ, Parsi KK, Schupp C, Armstrong AW.
Patient-centered online management of psoriasis: a randomized controlled equivalency trial.
J Am Acad Dermatol. 2012 Jun;66(6):948-53.

– Dastgheib L, Jowkar F, Abdollahee A, Namazi MR.
Mesalazine as a new therapeutic option for chronic idiopathic urticaria.
J Dermatolog Treat. 2012 Oct;23(5):323-9.

– Dauden E, Herrera E, Puig L, Sánchez-Carazo JL, Toribio J, Caloto MT, Nocea G, Roset M, Lara N.
Validation of a new tool to assess health-related quality of life in psoriasis: the PSO-LIFE questionnaire.
Health Qual Life Outcomes. 2012 May 24;10:56.

– Ersser SJ, Cowdell FC, Nicholls PG, Latter SM, Healy E.
A pilot randomized controlled trial to examine the feasibility and efficacy of an educational nursing intervention to improve self-management practices in patients with mild-moderate psoriasis.
J Eur Acad Dermatol Venereol. 2012 Jun;26(6):738-45.

– Fabbrocini G, Panariello L, De Vita V, Vincenzi C, Lauro C, Nappo D, Ayala F, Tosti A.
Quality of life in alopecia areata: a disease-specific questionnaire.
J Eur Acad Dermatol Venereol. 2012 Jul 3. doi: 10.1111/j.1468-3083.2012.04629.x. [Epub ahead of print]

– Farias MM, Achurra P, Boza C, Vega A, de la Cruz C.
Psoriasis following bariatric surgery: clinical evolution and impact on quality of life on 10 patients.
Obes Surg. 2012 Jun;22(6):877-80.

– Fernandez-Peñas P, Jones-Caballero M, Espallardo O, García-Díez A.
Comparison of Skindex-29, Dermatology Life Quality Index, Psoriasis Disability Index and Medical Outcome Study Short Form 36 in patients with mild to severe psoriasis.
Br J Dermatol. 2012 Apr;166(4):884-7.

– Finlay AY, Basra MK.
DLQI and CDLQI scores should not be combined.
Br J Dermatol. 2012 Aug;167(2):453-4.

– Finlay AY, Basra MK, Piguet V, Salek MS.
Dermatology life quality index (DLQI): a paradigm shift to patient-centered outcomes.
J Invest Dermatol. 2012 Oct;132(10):2464-5.

– Flytström I, Stenberg B, Svensson Å, Bergbrant IM.
Patients’ visual analogue scale: a useful method for assessing psoriasis severity.
Acta Derm Venereol. 2012 Jul;92(4):347-8.

– Frühauf J, Schwantzer G, Ambros-Rudolph CM, Weger W, Ahlgrimm-Siess V, Salmhofer W, Hofmann-Wellenhof R.
Pilot study on the acceptance of mobile teledermatology for the home monitoring of high-need patients with psoriasis.
Australas J Dermatol. 2012 Feb;53(1):41-6.

– Gelfand JM, Wan J, Callis Duffin K, Krueger GG, Kalb RE, Weisman JD, Sperber BR, Stierstorfer MB, Brod BA, Schleicher SM, Bebo BF Jr, Troxel AB, Shin DB, Steinemann JM, Goldfarb J, Yeung H, Van Voorhees AS.
Comparative effectiveness of commonly used systemic treatments or phototherapy for moderate to severe plaque psoriasis in the clinical practice setting.
Arch Dermatol. 2012 Apr;148(4):487-94.

– Ghajarzadeh M, Ghiasi M, Kheirkhah S.
Associations between skin diseases and quality of life: a comparison of psoriasis, vitiligo, and alopecia areata.
Acta Med Iran. 2012;50(7):511-5.

– Ghatnekar O, Ljungberg A, Wirestrand LE, Svensson A.
Costs and quality of life for psoriatic patients at different degrees of severity in southern Sweden – a cross-sectional study.
Eur J Dermatol. 2012 Mar-Apr;22(2):238-45.

– Ghodsi SZ, Chams-Davatchi C, Daneshpazhooh M, Valikhani M, Esmaili N.
Quality of life and psychological status of patients with pemphigus vulgaris using Dermatology Life Quality Index and General Health Questionnaires.
J Dermatol. 2012 Feb;39(2):141-4.

– Gniadecki R, Robertson D, Molta CT, Freundlich B, Pedersen R, Li W, Boggs R, Zbrozek AS.
Self-reported health outcomes in patients with psoriasis and psoriatic arthritis randomized to two etanercept regimens.
J Eur Acad Dermatol Venereol. 2012 Nov;26(11):1436-43.

– Goeksu Y, Zimmerli LU, Braun RP, Klaghofer R, French LE, Battegay E, Navarini AA.
Acutely ill patients in internal medicine departments want treatment for undiagnosed, symptomatic skin conditions.
Dermatology. 2012;225(2):115-20.

– Greenberger S, Harats D, Salameh F, Lubish T, Harari A, Trau H, Shaish A.
9-cis-rich β-carotene powder of the alga Dunaliella reduces the severity of chronic plaque psoriasis: a randomized, double-blind, placebo-controlled clinical trial.
J Am Coll Nutr. 2012 Oct;31(5):320-6.

– Gulliver WP, Jemec GB, Baker KA.
Experience with ustekinumab for the treatment of moderate to severe hidradenitis suppurativa.
J Eur Acad Dermatol Venereol. 2012 Jul;26(7):911-4.

– Hadley J, Tristani-Firouzi P, Hull C, Florell S, Cotter M, Hadley M.
Results of an investigator-initiated single-blind split-face comparison of photodynamic therapy and 5% imiquimod cream for the treatment of actinic keratoses.
Dermatol Surg. 2012 May;38(5):722-7.

– Haeck IM, ten Berge O, van Velsen SG, de Bruin-Weller MS, Bruijnzeel-Koomen CA, Knol MJ.
Moderate correlation between quality of life and disease activity in adult patients with atopic dermatitis.
J Eur Acad Dermatol Venereol. 2012 Feb;26(2):236-41.

– Hashimoto T, Kawakami T, Tsuruta D, Hamada T, Natsuaki Y, Fukuda S, Koga H, Sogame R, Ohyama B, Ono F, Karashima T, Nakama T, Dainichi T, Ishii N, Yasumoto S.
Low-dose cyclosporin improves the health-related quality of life in Japanese psoriasis patients dissatisfied with topical corticosteroid monotherapy.
Australas J Dermatol. 2012 Aug;53(3):202-6.

– Hawkins DM, Eide MJ, Lim HW.
Perception of xeroderma pigmentosum support group members of xeroderma pigmentosum lifestyle impact.
Photodermatol Photoimmunol Photomed. 2012 Dec;28(6):338-9.

– He Z, Lu C, Ou A, Fang J, Wang D, Deng J, Zhang Z, Yu J.
Reliability and validity of the Chinese version of the Psoriasis Disability Index (PDI) in Chinese patients with psoriasis.
Health Qual Life Outcomes. 2012 Apr 13;10:37.

– He J, Wang T, Dong J.
Excision of apocrine glands and axillary superficial fascia as a single entity for the treatment of axillary bromhidrosis.
J Eur Acad Dermatol Venereol. 2012 Jun;26(6):704-9.

– Hinterberger L, Müller CS, Vogt T, Pföhler C.
Adalimumab: a Treatment Option for Pyoderma Gangrenosum After Failure of Systemic Standard Therapies.
Dermatol Ther (Heidelb). 2012 Dec;2(1):6.

– Hong HC, Lupin M, O’Shaughnessy KF.
Clinical evaluation of a microwave device for treating axillary hyperhidrosis.
Dermatol Surg. 2012 May;38(5):728-35.

– Hrehorów E, Salomon J, Matusiak L, Reich A, Szepietowski JC.
Patients with psoriasis feel stigmatized.
Acta Derm Venereol. 2012 Jan;92(1):67-72.

– Huh SY, Na JI, Huh CH, Park KC.
The effect of photodynamic therapy using indole-3-acetic Acid and green light on acne vulgaris.
Ann Dermatol. 2012 Feb;24(1):56-60.

– Ibler KS, Jemec GB, Diepgen TL, Gluud C, Lindschou Hansen J, Winkel P, Thomsen SF, Agner T.
Skin care education and individual counselling versus treatment as usual in healthcare workers with hand eczema: randomised clinical trial.
BMJ. 2012 Dec 12;345:e7822.

– Igarashi A, Kato T, Kato M, Song M, Nakagawa H; Japanese Ustekinumab Study Group.
Efficacy and safety of ustekinumab in Japanese patients with moderate-to-severe plaque-type psoriasis: long-term results from a phase 2/3 clinical trial.
J Dermatol. 2012 Mar;39(3):242-52.

– Ingordo V, Cazzaniga S, Gentile C, Iannazzone SS, Cusano F, Naldi L.
Dermatology Life Quality Index score in vitiligo patients: a pilot study among young Italian males.
G Ital Dermatol Venereol. 2012 Feb;147(1):83-90.

– Jáuregui I, Bartra J, del Cuvillo A, Dávila I, Ferrer M, Montoro J, Mullol J, Sastre J, Valero A.
Bilastine and quality of life.
J Investig Allergol Clin Immunol. 2011;21 Suppl 3:16-23. Review.

– Kim DH, Li K, Seo SJ, Jo SJ, Yim HW, Kim CM, Kim KH, Kim do W, Kim MB, Kim JW, Ro YS, Park YL, Park CW, Lee SC, Cho SH.
Quality of life and disease severity are correlated in patients with atopic dermatitis.
J Korean Med Sci. 2012 Nov;27(11):1327-32.

– Kimball AB, Gordon KB, Fakharzadeh S, Yeilding N, Szapary PO, Schenkel B, Guzzo C, Li S, Papp KA.
Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial through up to 3 years.
Br J Dermatol. 2012 Apr;166(4):861-72.

– Kimball AB, Yu AP, Signorovitch J, Xie J, Tsaneva M, Gupta SR, Bao Y, Mulani PM.
The effects of adalimumab treatment and psoriasis severity on self-reported work productivity and activity impairment for patients with moderate to severe psoriasis.
J Am Acad Dermatol. 2012 Feb;66(2):e67-76.

– Kini SP, DeLong LK.
Overview of health status quality-of-life measures.
Dermatol Clin. 2012 Apr;30(2):209-21.

– Kluger N, Jacot W, Frouin E, Rigau V, Poujol S, Dereure O, Guillot B, Romieu G, Bessis D.
Permanent scalp alopecia related to breast cancer chemotherapy by sequential fluorouracil/epirubicin/cyclophosphamide (FEC) and docetaxel: a prospective study of 20 patients.
Ann Oncol. 2012 Nov;23(11):2879-84.

– Kluger N, Jokinen M, Krohn K, Ranki A.
What is the burden of living with autoimmune polyendocrinopathy candidiasis ectodermal dystrophy (APECED) in 2012? A health-related quality-of-life assessment in Finnish patients.
Clin Endocrinol (Oxf). 2013 Jul;79(1):134-41.

– Kocatürk E, Aktaş S, Türkoğlu Z, Kavala M, Zindanci I, Koc M, Can B, Südoğan S.
Autologous whole blood and autologous serum injections are equally effective as placebo injections in reducing disease activity in patients with chronic spontaneous urticaria: a placebo controlled, randomized, single-blind study.
J Dermatolog Treat. 2012 Dec;23(6):465-71.

– Kocatürk E, Weller K, Martus P, Aktas S, Kavala M, Sarigul S, Baiardini I, Canonica GW, Brzoza Z, Kalogeromitros D, Maurer M.
Turkish version of the chronic urticaria quality of life questionnaire: cultural adaptation, assessment of reliability and validity.
Acta Derm Venereol. 2012 Jul;92(4):419-25.

– Kurek A, Peters EM, Chanwangpong A, Sabat R, Sterry W, Schneider-Burrus S.
Profound disturbances of sexual health in patients with acne inversa.
J Am Acad Dermatol. 2012 Sep;67(3):422-8, 428.e1.

– Lambert J, Dowlatshahi EA, de la Brassinne M, Nijsten T.
A descriptive study of psoriasis characteristics, severity and impact among 3,269 patients: results of a Belgian cross sectional study (BELPSO).
Eur J Dermatol. 2012 Mar-Apr;22(2):231-7.

– Langenbruch AK, Radtke MA, Augustin M.
Quality of psoriasis care from the patients’ perspective–results of the national health care study PsoReal.
Eur J Dermatol. 2012 Jul-Aug;22(4):518-24.

– Lesage C, Adnot-Desanlis L, Perceau G, Bonnet M, Palot JP, Bernard P, Reguiaï Z.
Efficacy and tolerance of prolonged infliximab treatment of moderate-to-severe forms of hidradenitis suppurativa.
Eur J Dermatol. 2012 Sep-Oct;22(5):640-4.

– Liu JB, Yao MZ, Si AL, Xiong LK, Zhou H.
Life quality of Chinese patients with chronic urticaria as assessed by the dermatology life quality index.
J Eur Acad Dermatol Venereol. 2012 Oct;26(10):1252-7.

– Ljosaa TM, Mork C, Stubhaug A, Moum T, Wahl AK.
Skin pain and skin discomfort is associated with quality of life in patients with psoriasis.
J Eur Acad Dermatol Venereol. 2012 Jan;26(1):29-35.

– Lodén M, Wirén K, Smerud KT, Meland N, Hønnås H, Mørk G, Lützow-Holm C, Funk J, Meding B.
The effect of a corticosteroid cream and a barrier-strengthening moisturizer in hand eczema. A double-blind, randomized, prospective, parallel group clinical trial.
J Eur Acad Dermatol Venereol. 2012 May;26(5):597-601.

– Lu CJ, Xiang Y, Xie XL, Xuan ML, He ZH.
A randomized controlled single-blind clinical trial on 84 outpatients with psoriasis vulgaris by auricular therapy combined with optimized Yinxieling Formula.
Chin J Integr Med. 2012 Mar;18(3):186-91.

– Lucka TC, Pathirana D, Sammain A, Bachmann F, Rosumeck S, Erdmann R, Schmitt J, Orawa H, Rzany B, Nast A.
Efficacy of systemic therapies for moderate-to-severe psoriasis: a systematic review and meta-analysis of long-term treatment.
J Eur Acad Dermatol Venereol. 2012 Nov;26(11):1331-44.

– Mabuchi T, Yamaoka H, Kojima T, Ikoma N, Akasaka E, Ozawa A.
Psoriasis affects patient’s quality of life more seriously in female than in male in Japan.
Tokai J Exp Clin Med. 2012 Sep 20;37(3):84-8.

– Maksimović N, Janković S, Marinković J, Sekulović LK, Zivković Z, Spirić VT.
Health-related quality of life in patients with atopic dermatitis.
J Dermatol. 2012 Jan;39(1):42-7.

– Martins PR, Skare T, Ferrari TA, Silva AP, Alessio BF.
Comparative analysis of the quality of life of patients with discoid lupus erythematosus and systemic lupus erythematosus with skin injuries.
An Bras Dermatol. 2012 Mar-Apr;87(2):326-8.

– Maza A, Richard MA, Aubin F, Ortonne JP, Prey S, Bachelez H, Beylot-Barry M, Bulai-Livideanu C, Lahfa M, Nougué J, Mengual X, Le Moigne M, Lauwers-Cances V, Paul C
Significant delay in the introduction of systemic treatment of moderate to severe psoriasis: a prospective multicentre observational study in outpatients from hospital dermatology departments in France.
Br J Dermatol. 2012 Sep;167(3):643-8.

– Mease PJ.
Measures of psoriatic arthritis: Tender and Swollen Joint Assessment, Psoriasis Area and Severity Index (PASI), Nail Psoriasis Severity Index (NAPSI), Modified Nail Psoriasis Severity Index (mNAPSI), Mander/Newcastle Enthesitis Index (MEI), Leeds Enthesitis Index (LEI), Spondyloarthritis Research Consortium of Canada (SPARCC), Maastricht Ankylosing Spondylitis Enthesis Score (MASES), Leeds Dactylitis Index (LDI), Patient Global for Psoriatic Arthritis, Dermatology Life Quality Index (DLQI), Psoriatic Arthritis Quality of Life (PsAQOL), Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), Psoriatic Arthritis Response Criteria (PsARC), Psoriatic Arthritis Joint Activity Index (PsAJAI), Disease Activity in Psoriatic Arthritis (DAPSA), and Composite Psoriatic Disease Activity Index (CPDAI).
Arthritis Care Res (Hoboken). 2011 Nov;63 Suppl 11:S64-85.

– Menter MA, Caveney SW, Gottschalk RW.
Impact of clobetasol propionate 0.05% spray on health-related quality of life in patients with plaque psoriasis.
J Drugs Dermatol. 2012 Nov;11(11):1348-54.

– Müller C, Berensmeier A, Hamm H, Dirschka T, Reich K, Fischer T, Rzany B.
Efficacy and safety of methantheline bromide (Vagantin(®)) in axillary and palmar hyperhidrosis: results from a multicenter, randomized, placebo-controlled trial.
J Eur Acad Dermatol Venereol. 2012 Sep 25.

– Nakagawa H, Schenkel B, Kato M, Kato T, Igarashi A; Japanese Ustekinumab Study Group.
Impact of ustekinumab on health-related quality of life in Japanese patients with moderate-to-severe plaque psoriasis: results from a randomized, double-blind, placebo-controlled phase 2 / 3 trial.
J Dermatol. 2012 Sep;39(9):761-9.

– Nijsten T.
Dermatology life quality index: time to move forward.
J Invest Dermatol. 2012 Jan;132(1):11-3.

– Norlin JM, Steen Carlsson K, Persson U, Schmitt-Egenolf M. Switch to biological agent in psoriasis significantly improved clinical and patient-reported outcomes in real-world practice. Dermatology. 2012;225:326-32.

– Norlin JM, Steen Carlsson K, Persson U, Schmitt-Egenolf M.
Analysis of three outcome measures in moderate to severe psoriasis: a registry-based study of 2450 patients.
Br J Dermatol. 2012 Apr;166(4):797-802.

– Panahi Y, Davoudi SM, Madanchi N, Abolhasani E.
Recombinant human interferon gamma (Gamma Immunex) in treatment of atopic dermatitis.
Clin Exp Med. 2012 Dec;12(4):241-5.

– Panahi Y, Sahebkar A, Amiri M, Davoudi SM, Beiraghdar F, Hoseininejad SL, Kolivand M.
Improvement of sulphur mustard-induced chronic pruritus, quality of life and antioxidant status by curcumin: results of a randomised, double-blind, placebo-controlled trial.
Br J Nutr. 2012 Oct;108(7):1272-9.

– Panahi Y, Sahebkar A, Davoudi SM, Amiri M, Beiraghdar F.
Efficacy and safety of immunotherapy with interferon-gamma in the management of chronic sulfur mustard-induced cutaneous complications: comparison with topical betamethasone 1%.
ScientificWorldJournal. 2012;2012:285274.

– Panahi Y, Sahebkar A, Parvin S, Saadat A.
A randomized controlled trial on the anti-inflammatory effects of curcumin in patients with chronic sulphur mustard-induced cutaneous complications.
Ann Clin Biochem. 2012 Nov;49(Pt 6):580-8.

– Papp KA, Poulin Y, Bissonnette R, Bourcier M, Toth D, Rosoph L, Poulin-Costello M, Setterfield M, Syrotuik J.
Assessment of the long-term safety and effectiveness of etanercept for the treatment of psoriasis in an adult population.
J Am Acad Dermatol. 2012 Feb;66(2):e33-45.

– Parsi K, Chambers CJ, Armstrong AW.
Cost-effectiveness analysis of a patient-centered care model for management of psoriasis.
J Am Acad Dermatol. 2012 Apr;66(4):563-70.

– Paul C, van de Kerkhof P, Puig L, Unnebrink K, Goldblum O, Thaçi D.
Influence of psoriatic arthritis on the efficacy of adalimumab and on the treatment response of other markers of psoriasis burden: subanalysis of the BELIEVE study.
Eur J Dermatol. 2012 Nov-Dec;22(6):762-9.

– Pereira FR, Basra MK, Finlay AY, Salek MS.
The role of the EQ-5D in the economic evaluation of dermatological conditions and therapies.
Dermatology. 2012;225(1):45-53.

– Peuvrel L, Quéreux G, Brocard A, Saint-Jean M, Vallet C, Mère A, Labetoulle G, Le Fol C, Dréno B.
Evaluation of quality of life after a medical corrective make-up lesson in patients with various dermatoses.
Dermatology. 2012;224(4):374-80.

– Pflugfelder A, Welter AK, Leiter U, Weide B, Held L, Eigentler TK, Dirschka T, Stockfleth E, Nashan D, Garbe C; German Dermatologic Cooperative Oncology Group.
Open label randomized study comparing 3 months vs. 6 months treatment of actinic keratoses with 3% diclofenac in 2.5% hyaluronic acid gel: a trial of the German Dermatologic Cooperative Oncology Group.
J Eur Acad Dermatol Venereol. 2012 Jan;26(1):48-53.

– Prey S, Ezzedine K, Doussau A, Grandoulier AS, Barcat D, Chatelus E, Diot E, Durant C, Hachulla E, de Korwin-Krokowski JD, Kostrzewa E, Quemeneur T, Paul C, Schaeverbeke T, Seneschal J, Solanilla A, Sparsa A, Bouchet S, Lepreux S, Mahon FX, Chene G, Taïeb A.
Imatinib mesylate in scleroderma-associated diffuse skin fibrosis: a phase II multicentre randomized double-blinded controlled trial.
Br J Dermatol. 2012 Nov;167(5):1138-44.

– Radtke MA, Langenbruch AK, Schäfer I, Herberger K, Reich K, Augustin M.
Nail psoriasis as a severity indicator: results from the PsoReal study.
Patient Relat Outcome Meas. 2011 Jul;2:1-6

– Richetta AG, Mattozzi C, Giancristoforo S, D’Epiro S, Cantisani C, Macaluso L, Salvi M, Calvieri S.
Safety and efficacy of Adalimumab in the treatment of moderate to severe palmo-plantar psoriasis: an open label study.
Clin Ter. 2012;163(2):e61-6.

– Rider LG, Werth VP, Huber AM, Alexanderson H, Rao AP, Ruperto N, Herbelin L, Barohn R, Isenberg D, Miller FW.
Measures of adult and juvenile dermatomyositis, polymyositis, and inclusion body myositis: Physician and Patient/Parent Global Activity, Manual Muscle Testing (MMT), Health Assessment Questionnaire (HAQ)/Childhood Health Assessment Questionnaire (C-HAQ), Childhood Myositis Assessment Scale (CMAS), Myositis Disease Activity Assessment Tool (MDAAT), Disease Activity Score (DAS), Short Form 36 (SF-36), Child Health Questionnaire (CHQ), physician global damage, Myositis Damage Index (MDI), Quantitative Muscle Testing (QMT), Myositis Functional Index-2 (FI-2), Myositis Activities Profile (MAP), Inclusion Body Myositis Functional Rating Scale (IBMFRS), Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI), Cutaneous Assessment Tool (CAT), Dermatomyositis Skin Severity Index (DSSI), Skindex, and Dermatology Life Quality Index (DLQI).
Arthritis Care Res (Hoboken). 2011 Nov;63 Suppl 11:S118-57.

– Rogers A, DeLong LK, Chen SC.
Clinical meaning in skin-specific quality of life instruments: a comparison of the Dermatology Life Quality Index and Skindex banding systems.
Dermatol Clin. 2012 Apr;30(2):333-42.

– Rosen CF, Mussani F, Chandran V, Eder L, Thavaneswaran A, Gladman DD.
Patients with psoriatic arthritis have worse quality of life than those with psoriasis alone.
Rheumatology (Oxford). 2012 Mar;51(3):571-6.

– Safizadeh H, Shamsi-Meymandy S, Naeimi A.
Quality of life in Iranian patients with acne.
Dermatol Res Pract. 2012;2012:571516.

– Samrao A, Berry TM, Goreshi R, Simpson EL.
A pilot study of an oral phosphodiesterase inhibitor (apremilast) for atopic dermatitis in adults.
Arch Dermatol. 2012 Aug;148(8):890-7.

– Scheer F, Wins A, Kamusella P, Wiggermann P, Wissgott C, Andresen R.
[Clinical importance of CT-assisted sympathicolysis in primary, focal plantar and palmar hyperhidrosis].
Rofo. 2012 Jul;184(7):624-8.

– Sebaratnam DF, McMillan JR, Werth VP, Murrell DF.
Quality of life in patients with bullous dermatoses.
Clin Dermatol. 2012 Jan-Feb;30(1):103-7.

– Seité S, Deshayes P, Dréno B, Misery L, Reygagne P, Saiag P, Stengel F, Roguedas-Contios A, Rougier A.
Interest of corrective makeup in the management of patients in dermatology.
Clin Cosmet Investig Dermatol. 2012;5:123-8.

– Skiveren J, Mikkelsen MR, Daugbjerg H, Wulf HC.
Skin reactions and quality of life after x-ray therapy of Basal cell carcinoma.
J Skin Cancer. 2012;2012:825095.

– Simpson RC, Littlewood SM, Cooper SM, Cruickshank ME, Green CM, Derrick E, Yell J, Chiang N, Bell H, Owen C, Javed A, Wilson CL, McLelland J, Murphy R.
Real-life experience of managing vulval erosive lichen planus: a case-based review and U.K. multicentre case note audit.
Br J Dermatol. 2012 Jul;167(1):85-91.

– Skudlik C, Weisshaar E, Scheidt R, Elsner P, Wulfhorst B, Schönfeld M, John SM, Diepgen TL; ROQ Study Group.
First results from the multicentre study rehabilitation of occupational skin diseases–optimization and quality assurance of inpatient management (ROQ).
Contact Dermatitis. 2012 Mar;66(3):140-7.

– Sola-Ortigosa J, Sánchez-Regaña M, Umbert-Millet P.
Efficacy of adalimumab in the treatment of psoriasis: a retrospective study of 15 patients in daily practice.
J Dermatolog Treat. 2012 Jun;23(3):203-7.

– Sotiriou E, Goussi C, Lallas A, Chovarda E, Apalla Z, Lazaridou E, Ioannides D.
A prospective open-label clinical trial of efficacy of the every week administration of adalimumab in the treatment of hidradenitis suppurativa.
J Drugs Dermatol. 2012 May;11(5 Suppl):s15-20.

– Spuls PI, Hooft L.
Brodalumab and ixekizumab, anti-interleukin-17-receptor antibodies for psoriasis: a critical appraisal.
Br J Dermatol. 2012 Oct;167(4):710-3; discussion 714-5.

– Strober BE, Sobell JM, Duffin KC, Bao Y, Guérin A, Yang H, Goldblum O, Okun MM, Mulani PM.
Sleep quality and other patient-reported outcomes improve after patients with psoriasis with suboptimal response to other systemic therapies are switched to adalimumab: results from PROGRESS, an open-label Phase IIIB trial.
Br J Dermatol. 2012 Dec;167(6):1374-81.

– Tasoula E, Gregoriou S, Chalikias J, Lazarou D, Danopoulou I, Katsambas A, Rigopoulos D.
The impact of acne vulgaris on quality of life and psychic health in young adolescents in Greece. Results of a population survey.
An Bras Dermatol. 2012 Nov-Dec;87(6):862-9.

– Tennvall GR, Hjortsberg C, Bjarnason A, Gniadecki R, Heikkilä H, Jemec GB, Kragballe K, Miller IM, Svensson A.
Treatment patterns, treatment satisfaction, severity of disease problems, and quality of life in patients with psoriasis in three nordic countries.
Acta Derm Venereol. 2013 Jul 6;93(4):442-5.

– Torii H, Sato N, Yoshinari T, Nakagawa H; Japanese Infliximab Study Investigators.
Dramatic impact of a Psoriasis Area and Severity Index 90 response on the quality of life in patients with psoriasis: an analysis of Japanese clinical trials of infliximab.
J Dermatol. 2012 Mar;39(3):253-9.

– Traczewski P, Rudnicka L.
Briakinumab for the treatment of plaque psoriasis.
BioDrugs. 2012 Feb 1;26(1):9-20.

– Try C, Messikh R, Elkhyat A, Aubin F, Humbert RP.
[Use of oral oxybutynin at 7.5 mg per day in primary hyperhidrosis].
Rev Med Liege. 2012 Oct;67(10):520-6. French.

– Tsai TF, Song M, Shen YK, Schenkel B, Choe YB, Kim NI, Lee JH, Lee JH, Song HJ, Youn JI; PEARL investigators.
Ustekinumab improves health-related quality of life in Korean and Taiwanese patients with moderate to severe psoriasis: results from the PEARL trial.
J Drugs Dermatol. 2012 Aug;11(8):943-9.

– Twiss J, Meads DM, Preston EP, Crawford SR, McKenna SP.
Can we rely on the Dermatology Life Quality Index as a measure of the impact of psoriasis or atopic dermatitis?
J Invest Dermatol. 2012 Jan;132(1):76-84.

– Umar N, Litaker D, Schaarschmidt ML, Peitsch WK, Schmieder A, Terris DD.
Outcomes associated with matching patients’ treatment preferences to physicians’ recommendations: study methodology.
BMC Health Serv Res. 2012 Jan 3;12:1.

– van Rappard DC, Leenarts MF, Meijerink-van ‘t Oost L, Mekkes JR.
Comparing treatment outcome of infliximab and adalimumab in patients with severe hidradenitis suppurativa.
J Dermatolog Treat. 2012 Aug;23(4):284-9.

– Vender R, Lynde C, Gilbert M, Ho V, Sapra S, Poulin-Costello M.
Etanercept improves quality of life outcomes and treatment satisfaction in patients with moderate to severe plaque psoriasis in clinical practice.
J Cutan Med Surg. 2012 Nov-Dec;16(6):407-16.

– Vrijman C, Homan ML, Limpens J, van der Veen W, Wolkerstorfer A, Terwee CB, Spuls PI.
Measurement Properties of Outcome Measures for Vitiligo: A Systematic Review.
Arch Dermatol. 2012 Sep 17:1-8. doi: 10.1001/archdermatol.2012.3065. [Epub ahead of print]

– Wong SM, Baba R.
Quality of life among Malaysian patients with vitiligo.
Int J Dermatol. 2012 Feb;51(2):158-61.

– Worth C, Heukelbach J, Fengler G, Walter B, Liesenfeld O, Feldmeier H.
Impaired quality of life in adults and children with scabies from an impoverished community in Brazil.
Int J Dermatol. 2012 Mar;51(3):275-82.

– Yang HZ, Wang K, Jin HZ, Gao TW, Xiao SX, Xu JH, Wang BX, Zhang FR, Li CY, Liu XM, Tu CX, Ji SZ, Shen Y, Zhu XJ.
Infliximab monotherapy for Chinese patients with moderate to severe plaque psoriasis: a randomized, double-blind, placebo-controlled multicenter trial.
Chin Med J (Engl). 2012 Jun;125(11):1845-51.

– Yousefi M, Barikbin B, Kamalinejad M, Abolhasani E, Ebadi A, Younespour S, Manouchehrian M, Hejazi S.
Comparison of therapeutic effect of topical Nigella with Betamethasone and Eucerin in hand eczema.
J Eur Acad Dermatol Venereol. 2012 Dec 1. doi: 10.1111/jdv.12033. [Epub ahead of print]

– Yu M, Han TY, Lee JH, Son SJ.
The Quality of Life and Depressive Mood among Korean Patients with Hand Eczema.
Ann Dermatol. 2012 Nov;24(4):430-7.

– Zachariae C, Sand C, Hansen JM, Sørensen SS, Koch K, Villumsen J, Axelsen M.
Warts in a cohort of Danish kidney transplanted patients: impact on quality of life.
Acta Derm Venereol. 2012 Nov;92(6):615-8.

DLQI

Further Information

For general queries, technical aspects and permission to use:

E-mail: dermqol@cf.ac.uk

Other contacts:

Mrs Joy Hayes (financial aspects):
HayesJ@cf.ac.uk

Professor Andrew Y Finlay:
FinlayAY@cf.ac.uk

Address:
Department of Dermatology
Cardiff University School of Medicine
Heath Park, Cardiff
CF14 4XN
United Kingdom
Tel: +44 (0)29 2074 2884
Fax: +44 (0)29 2074 4321

FAQs

Quality of Life FAQs

Publications

Key References
Full Reference List